@manuscripts/transform 4.3.53 → 4.4.1

This diff represents the content of publicly available package versions that have been released to one of the supported registries. The information contained in this diff is provided for informational purposes only and reflects changes between package versions as they appear in their respective public registries.
Files changed (196) hide show
  1. package/dist/cjs/jats/__tests__/jats-roundtrip.test.js +3 -3
  2. package/dist/cjs/jats/exporter/jats-exporter.js +3 -0
  3. package/dist/cjs/jats/importer/jats-dom-parser.js +41 -1
  4. package/dist/cjs/schema/index.js +9 -0
  5. package/dist/cjs/schema/nodes/headshot_element.js +38 -0
  6. package/dist/cjs/schema/nodes/headshot_grid.js +37 -0
  7. package/dist/cjs/schema/nodes/headshot_image.js +51 -0
  8. package/dist/cjs/transformer/node-names.js +2 -0
  9. package/dist/cjs/transformer/node-title.js +6 -0
  10. package/dist/cjs/version.js +1 -1
  11. package/dist/es/jats/__tests__/jats-roundtrip.test.js +3 -3
  12. package/dist/es/jats/exporter/jats-exporter.js +3 -0
  13. package/dist/es/jats/importer/jats-dom-parser.js +41 -1
  14. package/dist/es/schema/index.js +9 -0
  15. package/dist/es/schema/nodes/headshot_element.js +34 -0
  16. package/dist/es/schema/nodes/headshot_grid.js +33 -0
  17. package/dist/es/schema/nodes/headshot_image.js +48 -0
  18. package/dist/es/transformer/node-names.js +2 -0
  19. package/dist/es/transformer/node-title.js +6 -0
  20. package/dist/es/version.js +1 -1
  21. package/dist/types/jats/__tests__/utils.d.ts +1 -1
  22. package/dist/types/schema/index.d.ts +3 -0
  23. package/dist/types/schema/nodes/headshot_element.d.ts +25 -0
  24. package/dist/types/schema/nodes/headshot_grid.d.ts +24 -0
  25. package/dist/types/schema/nodes/headshot_image.d.ts +26 -0
  26. package/dist/types/schema/types.d.ts +1 -1
  27. package/dist/types/version.d.ts +1 -1
  28. package/package.json +22 -21
  29. package/src/errors.ts +28 -0
  30. package/src/getVersion.ts +21 -0
  31. package/src/index.ts +28 -0
  32. package/src/jats/__tests__/__fixtures__/debug-example.xml +136 -0
  33. package/src/jats/__tests__/__fixtures__/jats-abstract-no-body.xml +163 -0
  34. package/src/jats/__tests__/__fixtures__/jats-citations.xml +472 -0
  35. package/src/jats/__tests__/__fixtures__/jats-comments.xml +46 -0
  36. package/src/jats/__tests__/__fixtures__/jats-document.xml +134 -0
  37. package/src/jats/__tests__/__fixtures__/jats-example-doc.xml +1235 -0
  38. package/src/jats/__tests__/__fixtures__/jats-example-front-only.xml +26 -0
  39. package/src/jats/__tests__/__fixtures__/jats-example-full.xml +209 -0
  40. package/src/jats/__tests__/__fixtures__/jats-example-no-back.xml +156 -0
  41. package/src/jats/__tests__/__fixtures__/jats-example-no-body.xml +91 -0
  42. package/src/jats/__tests__/__fixtures__/jats-example.xml +221 -0
  43. package/src/jats/__tests__/__fixtures__/jats-fn-group.xml +60 -0
  44. package/src/jats/__tests__/__fixtures__/jats-import-no-refs.xml +1077 -0
  45. package/src/jats/__tests__/__fixtures__/jats-import.xml +1578 -0
  46. package/src/jats/__tests__/__fixtures__/jats-roundtrip.xml +133 -0
  47. package/src/jats/__tests__/__fixtures__/jats-tables-example.xml +2043 -0
  48. package/src/jats/__tests__/__fixtures__/math-fragment.xml +12 -0
  49. package/src/jats/__tests__/__snapshots__/citeproc.test.ts.snap +57 -0
  50. package/src/jats/__tests__/__snapshots__/create-article-node.test.ts.snap +65 -0
  51. package/src/jats/__tests__/__snapshots__/jats-exporter.test.ts.snap +7 -0
  52. package/src/jats/__tests__/__snapshots__/jats-importer.test.ts.snap +59796 -0
  53. package/src/jats/__tests__/__snapshots__/jats-roundtrip.test.ts.snap +18 -0
  54. package/src/jats/__tests__/citations.ts +25 -0
  55. package/src/jats/__tests__/citeproc.test.ts +195 -0
  56. package/src/jats/__tests__/create-article-node.test.ts +29 -0
  57. package/src/jats/__tests__/data/section-categories.ts +212 -0
  58. package/src/jats/__tests__/files.ts +24 -0
  59. package/src/jats/__tests__/jats-exporter.test.ts +223 -0
  60. package/src/jats/__tests__/jats-importer.test.ts +567 -0
  61. package/src/jats/__tests__/jats-roundtrip.test.ts +66 -0
  62. package/src/jats/__tests__/utils.ts +90 -0
  63. package/src/jats/exporter/citeproc.ts +265 -0
  64. package/src/jats/exporter/jats-exporter.ts +2093 -0
  65. package/src/jats/exporter/jats-versions.ts +50 -0
  66. package/src/jats/exporter/labels.ts +101 -0
  67. package/src/jats/importer/create-article-node.ts +52 -0
  68. package/src/jats/importer/jats-comments.ts +111 -0
  69. package/src/jats/importer/jats-dom-parser.ts +1306 -0
  70. package/src/jats/importer/jats-parser-utils.ts +234 -0
  71. package/src/jats/importer/jats-transformations.ts +591 -0
  72. package/src/jats/importer/parse-jats-article.ts +106 -0
  73. package/src/jats/index.ts +21 -0
  74. package/src/jats/types.ts +16 -0
  75. package/src/lib/__tests__/footnotes.test.ts +36 -0
  76. package/src/lib/citeproc.ts +30 -0
  77. package/src/lib/credit-roles.ts +91 -0
  78. package/src/lib/deafults.ts +17 -0
  79. package/src/lib/footnotes.ts +85 -0
  80. package/src/lib/html.ts +56 -0
  81. package/src/lib/section-categories.ts +27 -0
  82. package/src/lib/utils.ts +145 -0
  83. package/src/lib/xml.ts +28 -0
  84. package/src/schema/__tests__/docs.ts +1911 -0
  85. package/src/schema/__tests__/groups.test.ts +61 -0
  86. package/src/schema/__tests__/migration.test.ts +23 -0
  87. package/src/schema/groups.ts +36 -0
  88. package/src/schema/index.ts +295 -0
  89. package/src/schema/marks.ts +254 -0
  90. package/src/schema/migration/migrate.ts +77 -0
  91. package/src/schema/migration/migration-script.ts +26 -0
  92. package/src/schema/migration/migration-scripts/1.2.5.ts +44 -0
  93. package/src/schema/migration/migration-scripts/2.3.22.ts +52 -0
  94. package/src/schema/migration/migration-scripts/3.0.12.ts +33 -0
  95. package/src/schema/migration/migration-scripts/3.0.21.ts +50 -0
  96. package/src/schema/migration/migration-scripts/3.0.30.ts +65 -0
  97. package/src/schema/migration/migration-scripts/3.0.31.ts +40 -0
  98. package/src/schema/migration/migration-scripts/3.0.41.ts +37 -0
  99. package/src/schema/migration/migration-scripts/3.0.55.ts +42 -0
  100. package/src/schema/migration/migration-scripts/3.0.56.ts +114 -0
  101. package/src/schema/migration/migration-scripts/4.2.13.ts +37 -0
  102. package/src/schema/migration/migration-scripts/4.2.15.ts +48 -0
  103. package/src/schema/migration/migration-scripts/4.3.23.ts +55 -0
  104. package/src/schema/migration/migration-scripts/4.3.34.ts +132 -0
  105. package/src/schema/migration/migration-scripts/4.3.35.ts +41 -0
  106. package/src/schema/migration/migration-scripts/index.ts +49 -0
  107. package/src/schema/nodes/abstracts.ts +29 -0
  108. package/src/schema/nodes/affiliation.ts +88 -0
  109. package/src/schema/nodes/affiliations.ts +30 -0
  110. package/src/schema/nodes/alt_text.ts +36 -0
  111. package/src/schema/nodes/alt_title.ts +40 -0
  112. package/src/schema/nodes/alt_titles_section.ts +58 -0
  113. package/src/schema/nodes/attachment.ts +46 -0
  114. package/src/schema/nodes/attachments.ts +45 -0
  115. package/src/schema/nodes/attribution.ts +38 -0
  116. package/src/schema/nodes/author_notes.ts +44 -0
  117. package/src/schema/nodes/award.ts +52 -0
  118. package/src/schema/nodes/awards.ts +45 -0
  119. package/src/schema/nodes/backmatter.ts +31 -0
  120. package/src/schema/nodes/bibliography_element.ts +58 -0
  121. package/src/schema/nodes/bibliography_item.ts +108 -0
  122. package/src/schema/nodes/bibliography_section.ts +60 -0
  123. package/src/schema/nodes/blockquote_element.ts +79 -0
  124. package/src/schema/nodes/body.ts +29 -0
  125. package/src/schema/nodes/box_element.ts +67 -0
  126. package/src/schema/nodes/caption.ts +67 -0
  127. package/src/schema/nodes/caption_title.ts +67 -0
  128. package/src/schema/nodes/citation.ts +70 -0
  129. package/src/schema/nodes/comment.ts +50 -0
  130. package/src/schema/nodes/comments.ts +28 -0
  131. package/src/schema/nodes/contributor.ts +87 -0
  132. package/src/schema/nodes/contributors.ts +40 -0
  133. package/src/schema/nodes/core_section.ts +27 -0
  134. package/src/schema/nodes/corresp.ts +49 -0
  135. package/src/schema/nodes/cross_reference.ts +64 -0
  136. package/src/schema/nodes/doc.ts +21 -0
  137. package/src/schema/nodes/embed.ts +55 -0
  138. package/src/schema/nodes/equation.ts +65 -0
  139. package/src/schema/nodes/equation_element.ts +61 -0
  140. package/src/schema/nodes/figure.ts +65 -0
  141. package/src/schema/nodes/figure_element.ts +73 -0
  142. package/src/schema/nodes/footnote.ts +95 -0
  143. package/src/schema/nodes/footnotes_element.ts +69 -0
  144. package/src/schema/nodes/footnotes_section.ts +61 -0
  145. package/src/schema/nodes/general_table_footnote.ts +42 -0
  146. package/src/schema/nodes/graphical_abstract_section.ts +62 -0
  147. package/src/schema/nodes/hard_break.ts +36 -0
  148. package/src/schema/nodes/headshot_element.ts +48 -0
  149. package/src/schema/nodes/headshot_grid.ts +46 -0
  150. package/src/schema/nodes/headshot_image.ts +65 -0
  151. package/src/schema/nodes/hero_image.ts +46 -0
  152. package/src/schema/nodes/highlight_marker.ts +68 -0
  153. package/src/schema/nodes/image_element.ts +49 -0
  154. package/src/schema/nodes/inline_equation.ts +68 -0
  155. package/src/schema/nodes/inline_footnote.ts +66 -0
  156. package/src/schema/nodes/keyword.ts +61 -0
  157. package/src/schema/nodes/keyword_group.ts +63 -0
  158. package/src/schema/nodes/keywords.ts +59 -0
  159. package/src/schema/nodes/keywords_element.ts +64 -0
  160. package/src/schema/nodes/link.ts +79 -0
  161. package/src/schema/nodes/list.ts +134 -0
  162. package/src/schema/nodes/listing.ts +91 -0
  163. package/src/schema/nodes/listing_element.ts +61 -0
  164. package/src/schema/nodes/long_desc.ts +36 -0
  165. package/src/schema/nodes/manuscript.ts +86 -0
  166. package/src/schema/nodes/missing_figure.ts +59 -0
  167. package/src/schema/nodes/paragraph.ts +77 -0
  168. package/src/schema/nodes/placeholder.ts +62 -0
  169. package/src/schema/nodes/placeholder_element.ts +60 -0
  170. package/src/schema/nodes/pullquote_element.ts +81 -0
  171. package/src/schema/nodes/quote_image.ts +64 -0
  172. package/src/schema/nodes/section.ts +69 -0
  173. package/src/schema/nodes/section_label.ts +39 -0
  174. package/src/schema/nodes/section_title.ts +58 -0
  175. package/src/schema/nodes/subtitle.ts +40 -0
  176. package/src/schema/nodes/subtitles.ts +51 -0
  177. package/src/schema/nodes/supplement.ts +77 -0
  178. package/src/schema/nodes/supplements.ts +60 -0
  179. package/src/schema/nodes/table.ts +144 -0
  180. package/src/schema/nodes/table_col.ts +76 -0
  181. package/src/schema/nodes/table_element.ts +67 -0
  182. package/src/schema/nodes/table_element_footer.ts +42 -0
  183. package/src/schema/nodes/text.ts +31 -0
  184. package/src/schema/nodes/title.ts +43 -0
  185. package/src/schema/nodes/trans_abstract.ts +58 -0
  186. package/src/schema/nodes/trans_graphical_abstract.ts +67 -0
  187. package/src/schema/types.ts +243 -0
  188. package/src/tests.ts +33 -0
  189. package/src/transformer/id.ts +23 -0
  190. package/src/transformer/index.ts +21 -0
  191. package/src/transformer/node-names.ts +75 -0
  192. package/src/transformer/node-title.ts +116 -0
  193. package/src/transformer/node-types.ts +39 -0
  194. package/src/transformer/node-validator.ts +82 -0
  195. package/src/types.ts +25 -0
  196. package/src/version.ts +1 -0
@@ -0,0 +1,1578 @@
1
+ <?xml version="1.0" encoding="utf-8"?>
2
+ <article article-type="research-article" dtd-version="1.1" xml:lang="en"
3
+ xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
4
+ <front>
5
+ <journal-meta>
6
+ <journal-id journal-id-type="publisher-id">APA6</journal-id>
7
+ <journal-id journal-id-type="nlm-ta">Brain Behav</journal-id>
8
+ <journal-title-group>
9
+ <journal-title>Brain and Behavior</journal-title>
10
+ <abbrev-journal-title abbrev-type="pubmed">Brain Behav.</abbrev-journal-title>
11
+ </journal-title-group>
12
+ <issn pub-type="epub">2162-3279</issn>
13
+ <publisher>
14
+ <publisher-name>John Wiley and Sons</publisher-name>
15
+ </publisher>
16
+ </journal-meta>
17
+ <article-meta>
18
+ <article-id pub-id-type="doi">10.5555/BRB3-2019-12-0787</article-id>
19
+ <article-id pub-id-type="publisher-id">BRB3-2019-12-0787</article-id>
20
+ <article-categories>
21
+ <subj-group subj-group-type="heading">
22
+ <subject>Original Research</subject>
23
+ </subj-group>
24
+ </article-categories>
25
+ <title-group>
26
+ <article-title>Blood <bold>pressure</bold> after follow up in a stroke prevention
27
+ clinic</article-title>
28
+ <alt-title alt-title-type="running">Running title example</alt-title>
29
+ <alt-title alt-title-type="short">Short title example</alt-title>
30
+ </title-group>
31
+ <contrib-group>
32
+ <contrib contrib-type="author" corresp="yes">
33
+ <contrib-id contrib-id-type="orcid" authenticated="true"
34
+ >https://orcid.org/0000-0003-2217-5904</contrib-id>
35
+ <name>
36
+ <surname>Hornnes</surname>
37
+ <given-names>Agnete Hviid</given-names>
38
+ <suffix>Jr.</suffix>
39
+ </name>
40
+ <degrees>RN</degrees>
41
+ <degrees>MPH</degrees>
42
+ <degrees>PhD</degrees>
43
+ <role> author </role>
44
+ <prefix> Mr </prefix>
45
+ <xref ref-type="aff" rid="BRB3-2019-12-0787-aff1" />
46
+ <role vocab="CRediT"
47
+ vocab-identifier="http://credit.niso.org/"
48
+ vocab-term="Writing – original draft"
49
+ vocab-term-identifier=
50
+ "http://credit.niso.org/contributor-roles/writing-original-draft/"
51
+ degree-contribution="lead">writer</role>
52
+ </contrib>
53
+ <contrib contrib-type="author">
54
+ <name>
55
+ <surname>Poulsen</surname>
56
+ <given-names>Mai Bang</given-names>
57
+ </name>
58
+ <degrees>MD</degrees>
59
+ <degrees>PhD</degrees>
60
+ <xref ref-type="fn" rid="BRB3-2019-12-0787-afn-0001">*</xref>
61
+ <xref ref-type="aff" rid="BRB3-2019-12-0787-aff1" />
62
+ </contrib>
63
+ <aff id="BRB3-2019-12-0787-aff1"><institution content-type="dept">Department of
64
+ Neurology</institution>, <institution>Herlev og Gentofte
65
+ Hospital</institution>, <addr-line>Borgmester Ib Juuls Vej 1</addr-line>,
66
+ <addr-line><postal-code>2730</postal-code>
67
+ <city>Herlev</city></addr-line>, <country>Denmark</country></aff>
68
+ </contrib-group>
69
+ <author-notes>
70
+ <corresp id="BRB3-2019-12-0787-cor1">Corresponding author: Agnete Hviid
71
+ Hornnes&#x2028;<email xlink:href="agnete.hviid.hornnes@regionh.dk"
72
+ >agnete.hviid.hornnes@regionh.dk</email>&#x2028;FAX: 0045 3868
73
+ 4031</corresp>
74
+ <fn id="BRB3-2019-12-0787-afn-0001">
75
+ <label>*</label>
76
+ <p>Mai Bang Poulsen, MD, PhD&#x2028;Department of
77
+ Neurology&#x2028;Nordsj&#x00E6;llands Hospital&#x2028;Dyrehavevej
78
+ 29&#x2028;3400 Hiller&#x00F8;d&#x2028;Denmark</p>
79
+ </fn>
80
+ <fn id="BRB3-2019-12-0787-afn-0002">
81
+ <p>ClinicalTrials.gov NCT03782857.</p>
82
+ </fn>
83
+ <fn fn-type="con">
84
+ <p content-type="fn-title">Contributor Information</p>
85
+ <p>Agnete Hviid Hornnes, Email: agnete.hviid.hornnes@regionh.dk <ext-link
86
+ ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-2217-5904"
87
+ >https//orcid.org/0000-0003-2217-5904</ext-link>&#x2028;Mai Bang
88
+ Poulsen, Email: mai.bang.poulsen.02@regionh.dk</p>
89
+ <p>Both authors have made substantial contributions to conception and design and
90
+ acquisitions and
91
+ analyses
92
+ <?AuthorQuery id="Q3" queryText="Check meaning - US English uses different spellings for the noun &quot;analyses&quot; (more than one analysis) and the verb form &quot;analyzes&quot;"?>
93
+ and interpretation of data and have; and been involved in writing the
94
+ manuscript and given final approval of the version to be published. Both
95
+ authors have participated sufficiently in the work to take public
96
+ responsibility for the content; and agree to be accountable for all aspects
97
+ of the work in ensuring that questions related to the accuracy or integrity
98
+ of any part of the work are appropriately investigated and resolved.</p>
99
+ </fn>
100
+ </author-notes>
101
+ <pub-date pub-type="ppub">
102
+ <year />
103
+ </pub-date>
104
+ <volume />
105
+ <supplementary-material id="S1" xlink:href="attachment:7d9d686b-5488-44a5-a1c5-46351e7f9312" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document">
106
+ <caption>
107
+ <title>final manuscript-hum-huili-dbh-suicide-20200707_figures (9)
108
+ </title>
109
+ </caption>
110
+ <alt-text>example of alt text for supplements</alt-text>
111
+ <long-desc>example of long desc for supplements</long-desc>
112
+ </supplementary-material>
113
+ <history>
114
+ <date date-type="received">
115
+ <day>09</day>
116
+ <month>12</month>
117
+ <year>2019</year>
118
+ </date>
119
+ <date date-type="rev-recd">
120
+ <day />
121
+ <month />
122
+ <year />
123
+ </date>
124
+ <date date-type="accepted">
125
+ <day>27</day>
126
+ <month>04</month>
127
+ <year>2020</year>
128
+ </date>
129
+ </history>
130
+ <permissions> </permissions>
131
+ <self-uri content-type="document"
132
+ xlink:href="http://www.harmreductionjournal.com/content/1/1/5" />
133
+ <self-uri content-type="document"
134
+ xlink:href="http://www.harmreductionjournal.com/content/1/1/2" />
135
+
136
+ <abstract>
137
+ <sec>
138
+ <title>Objectives</title>
139
+ <p>In Denmark 25% of hospital admissions with stroke are recurrent strokes. With
140
+ thrombolytic treatment more patients survive with only minor disability.
141
+ This promising development should be followed up by intensive secondary
142
+ prevention. Hypertension is the most important target. We aimed at testing
143
+ the hypotheses that early follow up in a preventive clinic would result in
144
+ 1) A higher proportion of patients with blood pressure at target, 2) Time to
145
+ stroke recurrence, myocardial infarction and death would be longer in the
146
+ intervention group compared to controls.</p>
147
+ </sec>
148
+ <sec>
149
+ <title>Materials and Methods</title>
150
+ <p>Eligible patients admitted to the stroke unit of Herlev Hospital were
151
+ randomized shortly before discharge to intervention or control group. Of 78
152
+ included participants data from 73 was available for follow up nine months
153
+ after inclusion. Patients in the intervention group were seen in the clinic
154
+ within one week. In case of hypertension treatment was initiated or supplied
155
+ with a new drug. We used individual targets for blood pressure according to
156
+ diagnosis of stroke and patients&#x2019; comorbidity. Patients in the
157
+ intervention group had a median of five visits to the preventive clinic.</p>
158
+ </sec>
159
+ <sec>
160
+ <title>Results</title>
161
+ <p content-type="headshots">
162
+ <graphic xlink:href="headshot.png">
163
+ <caption>
164
+ <title>Jane Doe, Ph.D.</title>
165
+ <p><bold>Editor</bold></p>
166
+ <p>Wiley</p>
167
+ </caption>
168
+ </graphic>
169
+ <graphic xlink:href="headshot2.png">
170
+ <alt-text>Headshot of Jack Black</alt-text>
171
+ <caption>
172
+ <title>Jack Black</title>
173
+ <p><bold>CEO</bold></p>
174
+ <p>Generico</p>
175
+ </caption>
176
+ </graphic>
177
+ </p>
178
+ <p>In the intervention group blood pressure was treated to target in 25 patients
179
+ (69%) versus 14 (38%) in the control group
180
+ (<italic>p</italic>&#x2009;=&#x2009;0.007). Median time to first event was
181
+ 44 months (4&#x2013;49) in the intervention group and 19 months
182
+ (4&#x2013;37) in controls (<italic>p</italic>&#x2009;=&#x2009;0.316).</p>
183
+ </sec>
184
+ <sec>
185
+ <title>Conclusions</title>
186
+ <p>Treatment of hypertension to individual targets after stroke is feasible. It
187
+ may postpone recurrent stroke and death in stroke survivors.</p>
188
+ </sec>
189
+ </abstract>
190
+ <abstract abstract-type="graphical">
191
+ <fig id="fig-1" position="anchor" fig-type="half-left">
192
+ <graphic xlink:href="demo1.jpg" />
193
+ </fig>
194
+ </abstract>
195
+ <abstract abstract-type="key-image">
196
+ <fig id="fig-2" position="anchor" fig-type="half-left">
197
+ <graphic xlink:href="demo2.jpg" />
198
+ </fig>
199
+ </abstract>
200
+ <abstract abstract-type="short">
201
+ <p>The is the third and last part of the volume devoted to solubility data of rare
202
+ earth metal chlorides in water and in ternary and quaternary aqueous systems.
203
+ Compilations of all available experimental data are introduced for each rare earth
204
+ metal chloride with a corresponding critical evaluation. This part covers chlorides
205
+ of Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu, with coverage of the literature through the
206
+ middle of 2008.</p>
207
+ </abstract>
208
+ <trans-abstract abstract-type="short" xml:lang="fr">
209
+ <p>
210
+ Il s'agit de la troisième et dernière partie du volume consacrée aux données de solubilité
211
+ des chlorures de métaux des terres rares dans l'eau et dans les systèmes aqueux ternaires
212
+ et
213
+ quaternaires.
214
+ Une compilation de toutes les données expérimentales disponibles est présentée pour chaque
215
+ chlorure de métaux des terres rares, accompagnée de l'évaluation critique correspondante.
216
+ Cette partie couvre les chlorures de Gd, Tb, Dy, Ho, Er, Tm, Yb et Lu, avec une couverture
217
+ de la littérature jusqu'à mi-2008.
218
+ </p>
219
+ </trans-abstract>
220
+ <kwd-group kwd-group-type="author">
221
+ <title>KEYWORDS &#x2028;</title>
222
+ <kwd>secondary prevention</kwd>
223
+ <kwd>stroke recurrence</kwd>
224
+ <kwd>blood pressure</kwd>
225
+ <kwd>blood pressure target</kwd>
226
+ <kwd>randomized controlled trial</kwd>
227
+ </kwd-group>
228
+ <funding-group>
229
+ <award-group>
230
+ <funding-source>National Institutes of Health</funding-source>
231
+ <principal-award-recipient>Berkeley</principal-award-recipient>
232
+ <award-id>GM18458</award-id>
233
+ </award-group>
234
+ <award-group>
235
+ <funding-source>National Science Foundation</funding-source>
236
+ <award-id>DMS-0204674</award-id>
237
+ <award-id>DMS-0244638</award-id>
238
+ </award-group>
239
+ </funding-group>
240
+ <counts>
241
+ <count count-type="box" count="0"/>
242
+ <fig-count count="3"/>
243
+ <table-count count="2"/>
244
+ <equation-count count="0"/>
245
+ <ref-count count="25"/>
246
+ <word-count count="4484"/>
247
+ </counts>
248
+ </article-meta>
249
+ </front>
250
+ <body>
251
+ <graphic xlink:href="demo1.png">
252
+ <ext-link xlink:href="WLYSP_5_4_Infographic_Nov_11_2022.pdf"/>
253
+ <caption>
254
+ <title>Title...</title>
255
+ <p>simple image</p>
256
+ <p>caption</p>
257
+ </caption>
258
+ </graphic>
259
+ <graphic
260
+ xlink:href="prodbe.int.aip.org:8080/journal/journal_fs/
261
+ 1.2983775.1373315697!/images/1460725790.jpg">
262
+ <alt-text>example of alt text for graphics</alt-text>
263
+ <long-desc>example of long desc</long-desc>
264
+ </graphic>
265
+ <p>test paragraph</p>
266
+ <disp-quote content-type="quote-with-image">
267
+ <graphic content-type="headshot" xlink:href="demo1.jpg"/>
268
+ <p>It is a far, far better thing that I do now than I have ever done.</p>
269
+ <attrib>Charles Dickens</attrib>
270
+ </disp-quote>
271
+ <sec id="BRB3-2019-12-0787-sec1" sec-type="intro">
272
+ <label>1</label>
273
+ <title>INTRODUCTION</title>
274
+ <p>Over the last two decades continuous development of thrombolytic treatment of acute
275
+ ischemic stroke (IS) has improved safety and functional outcome in treated patients
276
+ <xref ref-type="bibr"
277
+ rid="BRB3-2019-12-0787-bib-0001 BRB3-2019-12-0787-bib-0002"
278
+ ><sup>1;2</sup></xref> thus increasing the possibility of survival with no or
279
+ only minor disability. With this fact and the ongoing aging of populations in mind
280
+ <xref ref-type="bibr" rid="BRB3-2019-12-0787-bib-0003"><sup>3</sup></xref> the
281
+ secondary prevention after stroke seems more important than ever. In 1998 the
282
+ Copenhagen Stroke Study reported a recurrence rate of 23%. <xref ref-type="bibr"
283
+ rid="BRB3-2019-12-0787-bib-0004"><sup>4</sup></xref> According to the Danish
284
+ Stroke Registry our national recurrence rate was 25% in 2011.<xref ref-type="bibr"
285
+ rid="BRB3-2019-12-0787-bib-0005"><sup>5</sup></xref></p>
286
+ <p>Hypertension is an important risk factor for stroke recurrence. <xref ref-type="bibr"
287
+ rid="BRB3-2019-12-0787-bib-0004 BRB3-2019-12-0787-bib-0006 BRB3-2019-12-0787-bib-0007 BRB3-2019-12-0787-bib-0008"
288
+ ><sup>4;6&#x2013;8</sup></xref> Lowering blood pressure (BP) after stroke or
289
+ transitory ischemic attack (TIA) by 10/5 mm Hg has been associated with reduced risk
290
+ of stroke recurrence by 24% and myocardial infarction (MI) by 21%. <xref
291
+ ref-type="bibr" rid="BRB3-2019-12-0787-bib-0009"><sup>9</sup></xref></p>
292
+ <p>Observational studies have demonstrated the difficulties in lowering BP after stroke
293
+ with rates of BP treated to target ranging from 28% to 73% <xref ref-type="bibr"
294
+ rid="BRB3-2019-12-0787-bib-0010 BRB3-2019-12-0787-bib-0011 BRB3-2019-12-0787-bib-0012 BRB3-2019-12-0787-bib-0013"
295
+ ><sup>10&#x2013;13</sup></xref> and interventions aimed at control of BP
296
+ after stroke have not yet found a successful model. <xref ref-type="bibr"
297
+ rid="BRB3-2019-12-0787-bib-0014 BRB3-2019-12-0787-bib-0015 BRB3-2019-12-0787-bib-0016 BRB3-2019-12-0787-bib-0017 BRB3-2019-12-0787-bib-0018 BRB3-2019-12-0787-bib-0019"
298
+ ><sup>14&#x2013;19</sup></xref> Fahey and coworkers have reviewed the
299
+ literature aimed at improving control of BP in hypertensive subjects. One large
300
+ study using an organized system of regular visits to a clinic was efficient in
301
+ producing a large decrease in BP and reduction of all-cause mortality compared to
302
+ referral to usual primary care. This was achieved by using a stepwise escalation of
303
+ treatment until target was reached. <xref ref-type="bibr"
304
+ rid="BRB3-2019-12-0787-bib-0020"><sup>20</sup></xref> Other methods had variable
305
+ or no effect, only nurse or pharmacist led care seemed promising.</p>
306
+ <media
307
+ xmlns:xlink="http://www.w3.org/1999/xlink"
308
+ xlink:href="example.mp4"
309
+ xlink:show="embed"
310
+ mimetype="video"
311
+ mime-subtype="mp4" >
312
+ <alt-text>example of alt text for media</alt-text>
313
+ <long-desc>example of long desc</long-desc>
314
+ </media>
315
+ <sec>
316
+ <title>Aims and hypotheses</title>
317
+ <p>The aim of the present study was to test the hypotheses that follow up after
318
+ stroke in a specialized nurse led physician supervised clinic with stepwise
319
+ escalation of BP- and lipid lowering treatment would result in</p>
320
+ <sec>
321
+ <title>Primary endpoint</title>
322
+ <sec>
323
+ <title>A greater proportion of participants with BP at target</title>
324
+ <p>Secondary endpoints:<list id="L1" list-type="simple">
325
+ <list-item>
326
+ <p>A greater reduction of BP</p>
327
+ </list-item>
328
+ <list-item>
329
+ <p>A greater proportion of participants with LDL-cholesterol
330
+ treated to target</p>
331
+ </list-item>
332
+ <list-item>
333
+ <p>A greater reduction of LDL-cholesterol</p>
334
+ </list-item>
335
+ <list-item>
336
+ <p>Longer time to recurrence of stroke, MI and death</p>
337
+ </list-item>
338
+ <list-item>
339
+ <p>in the intervention group compared to controls</p>
340
+ </list-item>
341
+ </list>
342
+ </p>
343
+ </sec>
344
+ </sec>
345
+ <sec>
346
+ <title>BoxedText test</title>
347
+ <boxed-text></boxed-text>
348
+ <boxed-text>
349
+ <label>BoxedTextLabel</label>
350
+ <caption>
351
+ <title>BoxedTextCaptionTitle</title>
352
+ </caption>
353
+ <sec>
354
+ <title>Key messages</title>
355
+ <list list-type="bullet">
356
+ <list-item>
357
+ <p>The benefits of geriatric day hospital care have been
358
+ controversial for many years.</p>
359
+ </list-item>
360
+ <list-item>
361
+ <p>This systematic review of 12 randomised trials comparing
362
+ a variety of day hospitals with a range of alternative
363
+ services found no overall advantage for day hospital care.</p>
364
+ </list-item>
365
+ <list-item>
366
+ <p>Day hospitals had a possible advantage over no comprehensive
367
+ care in terms of death or poor outcome, disability, and use of
368
+ resources.</p>
369
+ </list-item>
370
+ <list-item>
371
+ <p>The costs of day hospital care may be partly offset by
372
+ a reduced use of hospital beds and institutional care among
373
+ survivors.</p>
374
+ </list-item>
375
+ </list>
376
+ </sec>
377
+ <sec>
378
+ <title>testing multiple sections inside a boxed-text element</title>
379
+ <p>Hello World!</p>
380
+ </sec>
381
+ </boxed-text>
382
+ <boxed-text>
383
+ <label>BoxedTextLabel</label>
384
+
385
+ <sec>
386
+ <title>Key messages</title>
387
+ <list list-type="bullet">
388
+ <list-item>
389
+ <p>The benefits of geriatric day hospital care have been
390
+ controversial for many years.</p>
391
+ </list-item>
392
+ <list-item>
393
+ <p>This systematic review of 12 randomised trials comparing
394
+ a variety of day hospitals with a range of alternative
395
+ services found no overall advantage for day hospital care.</p>
396
+ </list-item>
397
+ <list-item>
398
+ <p>Day hospitals had a possible advantage over no comprehensive
399
+ care in terms of death or poor outcome, disability, and use of
400
+ resources.</p>
401
+ </list-item>
402
+ <list-item>
403
+ <p>The costs of day hospital care may be partly offset by
404
+ a reduced use of hospital beds and institutional care among
405
+ survivors.</p>
406
+ </list-item>
407
+ </list>
408
+ </sec>
409
+ </boxed-text>
410
+ </sec>
411
+ </sec>
412
+ </sec>
413
+ <sec id="BRB3-2019-12-0787-sec2" sec-type="methods">
414
+ <label>2</label>
415
+ <title>MATERIELS AND METHODS</title>
416
+ <p>Before the initiation of the study the authors attended a three-day course in
417
+ treatment of hypertension arranged by the Danish Society of Hypertension. The
418
+ recommendations of our national guidelines regarding BP targets were in line with
419
+ those given by the American Stroke Association in force at the time of initiation of
420
+ the study: &#x201C;An absolute target BP level and reduction are uncertain and
421
+ should be individualized.&#x201D; <xref ref-type="bibr"
422
+ rid="BRB3-2019-12-0787-bib-0021"><sup>21</sup></xref> Following the advice given
423
+ by the Danish Society of Hypertension we used the following targets: A BP
424
+ &lt;&#x2009;140/90 mm Hg was considered at target in non-diabetic patients. In
425
+ patients aged 80 years or more a BP of 150/90 mm Hg was acceptable if further
426
+ treatment was not tolerated. In case of severe carotid stenosis or a history of
427
+ ischemic heart disease BP should not be lower than 130/80 mm Hg. In patients with
428
+ diabetes or hemorrhagic stroke we aimed at a BP&#x2009;&lt;&#x2009;130/80 mm Hg.
429
+ Untreated patients without hypertension were categorized as normotensive, untreated
430
+ hypertensive patients as having unknown hypertension, treated patients without
431
+ hypertension as treated to target, and treated patients with hypertension as having
432
+ untreated hypertension.</p>
433
+ <p>LDL-cholesterol should be &lt;&#x2009;2.5 mmol/l in patients with IS or TIA in
434
+ non-diabetic patients and in case of diabetes &lt;&#x2009;2.0 mmol/l.</p>
435
+ <p>A sample size calculation showed that 24 patients in each group were needed to show a
436
+ difference of 10 mm Hg in the development of systolic BP (80% power).</p>
437
+ <sec id="BRB3-2019-12-0787-sec2.1">
438
+ <label>2.1</label>
439
+ <title>Study sample and setting</title>
440
+ <p>From June 2012 to February 2013 all patients diagnosed with a stroke or TIA at
441
+ the stroke unit of Herlev Gentofte Hospital, University of Copenhagen were
442
+ considered for inclusion in the study. Patients should be without cognitive
443
+ deficits that would prevent their active participation and they should be
444
+ discharged to their own home. The last author used computer-generated block
445
+ randomization procedures with stratification by hypertension (1:1). The
446
+ allocation sequence was concealed, and we aimed at equal numbers in the two
447
+ groups. Shortly before discharge the first author approached eligible patients
448
+ for oral and written information about the study. Where written informed consent
449
+ to participation was achieved BP was measured before a concealed envelope
450
+ administered by a secretary was opened revealing the allocation to either
451
+ intervention or control group.</p>
452
+ <p>The research protocol was approved by the ethics committee of the Capital Region
453
+ of Denmark (H-3-2011&#x2013;152) and by the Danish Data Protection Agency
454
+ (2012&#x2013;41-0429). The study was conducted according to all common ethical
455
+ standards including the rules given by the Declaration of Helsinki. Patients
456
+ randomized to the control group had the usual treatment: one visit in the
457
+ outpatient clinic of the stroke unit three months after discharge. Patients
458
+ randomized to the intervention group had an appointment with the first author
459
+ within one week after discharge. The first author undertook all visits in the
460
+ preventive clinic.</p>
461
+ </sec>
462
+ <sec id="BRB3-2019-12-0787-sec2.2">
463
+ <label>2.2</label>
464
+ <title>Procedures and intervention</title>
465
+ <p>BP was measured at every visit after at least five minutes rest in a sitting
466
+ position in an arm chair. BP was measured simultaneously in both arms followed
467
+ by two measurements with 10-min intervals using the arm with the highest
468
+ systolic BP. In case of hypertension the first author would suggest initiation
469
+ or intensification of antihypertensive treatment. The last author would accept
470
+ or suggest an alternative and do the prescription. Patients would come to the
471
+ clinic for control of BP and relevant blood tests every 3&#x2013;4 weeks until
472
+ BP was at target. After five weeks on lipid lowering drugs treatment was
473
+ intensified if needed. Patients who did not tolerate lipid lowering medication
474
+ were referred to a dietitian. In motivated patients home BP measurements were
475
+ performed using patients&#x2019; own monitor or by lending patients a BP monitor
476
+ between visits.</p>
477
+ <p>Patients in the intervention group had a mean of five visits to the clinic with
478
+ addition of new drugs rather than adding more of the same drug in case of
479
+ hypertension. Although we used minimum doses to prevent adverse effects, many
480
+ patients had unacceptable side effects necessitating change to another class of
481
+ antihypertensive drug.</p>
482
+ <p>Patients were informed about the importance of life-long adherence with all
483
+ preventive medication. Those with elevated BP or receiving antihypertensive
484
+ treatment were advised in salt reduction, smokers were advised to stop smoking
485
+ and all patients were informed about the benefits of 30 min of moderate physical
486
+ activity daily. Likewise, information about the risk of an intake of alcohol
487
+ above seven drinks per week in women and 14 drinks in men was part of the
488
+ program as well as the benefits of weight reduction in overweight patients with
489
+ hypertension or diabetes.</p>
490
+ </sec>
491
+ <sec id="BRB3-2019-12-0787-sec2.3">
492
+ <label>2.3</label>
493
+ <title>Follow up</title>
494
+ <p>Participants in both groups were invited to the usual follow up visit three
495
+ months after discharge at the outpatient clinic of the stroke unit as well as a
496
+ follow up visit in the study a median of 9 (IQR 8&#x2013;11) months after
497
+ inclusion.</p>
498
+ <p>In accordance with the protocol the final follow up visits were performed by
499
+ nurses in the outpatient clinic with measurement of BP and blood-cholesterols.
500
+ Patients were asked not to reveal their group allocation but blinding of the
501
+ nurses was not possible. Patients were interviewed about adherence to all
502
+ preventive medications as well as their present life style. For practical
503
+ purposes a minority of visits were performed by the first author. To do
504
+ intention to treat
505
+ analyses<?AuthorQuery id="Q1" queryText="Check meaning - US English uses different spellings for the noun &quot;analyses&quot; (more than one analysis) and the verb form &quot;analyzes&quot;"?>
506
+ we used last observation carried forward regarding the endpoints of the study
507
+ where patients had died or did not respond to the invitation to a follow up
508
+ visit. Thus, we used the last recorded values in five patients in the
509
+ intervention group and in seven controls.</p>
510
+ <p>After a median of 65 months (IQR: 61&#x2013;66) from inclusion data on vascular
511
+ events and death were attained from the hospital based medical records covering
512
+ all hospitals of the region.</p>
513
+ </sec>
514
+ <sec id="BRB3-2019-12-0787-sec2.4">
515
+ <label>2.4</label>
516
+ <title>Statistics</title>
517
+ <p>Data were entered into Excel and imported into SAS. Statistical
518
+ analyses<?AuthorQuery id="Q2" queryText="Check meaning - US English uses different spellings for the noun &quot;analyses&quot; (more than one analysis) and the verb form &quot;analyzes&quot;"?>
519
+ were performed by the first author according to a pre-established statistical
520
+ analysis plan. We used Chi square test (for the primary outcome) or
521
+ Fisher&#x2019;s exact test as appropriate for comparison of proportions, and for
522
+ change from baseline we used McNemar&#x2019;s test. For continuous variables we
523
+ used t-test or Mann-Whitney&#x2019;s test*. Change from baseline was analyzed by
524
+ the paired t-test or Wilcoxon signed rank sum test* (*where data were not
525
+ normally distributed). We used SAS 9.4 for Windows and
526
+ <italic>p</italic>&#x2009;&lt;&#x2009;0.05 was considered significant.</p>
527
+ </sec>
528
+ </sec>
529
+ <sec id="BRB3-2019-12-0787-sec3" sec-type="results">
530
+ <label>3</label>
531
+ <title>RESULTS</title>
532
+ <p>We included 78 patients in the study. Due to revision of stroke diagnoses in four
533
+ participants and as one participant never turned up for the intervention, data on 73
534
+ participants were available for follow up (<xref ref-type="fig"
535
+ rid="BRB3-2019-12-0787-fig-0001">Figure 1</xref>). The median stay in hospital
536
+ was 4 days (IQR: 3&#x2013;6). As seen from <xref ref-type="table"
537
+ rid="BRB3-2019-12-0787-tbl-0001">Table 1</xref> most participants had no or
538
+ slight disability.</p>
539
+ <fig id="BRB3-2019-12-0787-fig-0001" position="float" fig-type="half-left">
540
+ <label>FIGURE 1</label>
541
+ <caption>
542
+ <p>Flow chart of participants</p>
543
+ </caption>
544
+ <alt-text>example of alt text for figs</alt-text>
545
+ <long-desc>example of long desc</long-desc>
546
+ <graphic xlink:href="BRB3-2019-12-0787-fig-0001.png">
547
+ <alt-text>example of alt text for graphics inside figures</alt-text>
548
+ <long-desc>example of long desc for graphics inside figures</long-desc>
549
+ </graphic>
550
+ </fig>
551
+ <table-wrap id="BRB3-2019-12-0787-tbl-0001" position="float">
552
+ <label>TABLE 1</label>
553
+ <caption>
554
+ <title>Baseline characteristics of 73 patients</title>
555
+ </caption>
556
+ <alt-text>example of alt text for tables</alt-text>
557
+ <long-desc>example of long desc</long-desc>
558
+ <table frame="hsides" rules="groups">
559
+ <col width="52.14%"/>
560
+ <col width="11.92%"/>
561
+ <col width="14.9%"/>
562
+ <col width="13.1%"/>
563
+ <col width="7.94%"/>
564
+ <thead>
565
+ <tr>
566
+ <th valign="top" align="left" scope="col"
567
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
568
+ >Characteristics</th>
569
+ <th valign="top" align="left" scope="col"
570
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
571
+ >All<break/>(<italic>n</italic>&#x2009;=&#x2009;73)</th>
572
+ <th valign="top" align="left" scope="col"
573
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
574
+ >Intervention (<italic>n</italic>&#x2009;=&#x2009;36)</th>
575
+ <th valign="top" align="left" scope="col"
576
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
577
+ >Control (<italic>n</italic>&#x2009;=&#x2009;37)</th>
578
+ <th valign="top" align="left" scope="col"
579
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt">P</th>
580
+ </tr>
581
+ </thead>
582
+ <tbody>
583
+ <tr>
584
+ <td valign="middle" align="left" style="border-top: solid 0.50pt"
585
+ scope="row">Sex, female</td>
586
+ <td valign="middle" align="left" style="border-top: solid 0.50pt">29
587
+ (40)</td>
588
+ <td valign="middle" align="left" style="border-top: solid 0.50pt">15
589
+ (42)</td>
590
+ <td valign="middle" align="left" style="border-top: solid 0.50pt">14
591
+ (38)</td>
592
+ <td valign="middle" align="left" style="border-top: solid 0.50pt"
593
+ >0.74</td>
594
+ </tr>
595
+ <tr>
596
+ <td valign="middle" align="left" scope="row">Age (years),
597
+ mean&#x2009;&#x00B1;&#x2009;SD</td>
598
+ <td valign="middle" align="left">66&#x2009;&#x00B1;&#x2009;12</td>
599
+ <td valign="middle" align="left">63&#x2009;&#x00B1;&#x2009;13</td>
600
+ <td valign="middle" align="left">68&#x2009;&#x00B1;&#x2009;11</td>
601
+ <td valign="middle" align="left">0.08</td>
602
+ </tr>
603
+ <tr>
604
+ <td valign="top" align="left" scope="row">Length of
605
+ education<break/>&lt;&#x2009;10 years<break/>10 &#x2013; 12
606
+ years<break/>&gt;&#x2009;12 years</td>
607
+ <td valign="top" align="left">12 (17)<break/>22 (30)<break/>38 (53)</td>
608
+ <td valign="top" align="left">6 (17)<break/>10 (29)<break/>19 (54)</td>
609
+ <td valign="top" align="left">6 (16)<break/>12 (33)<break/>19 (51)</td>
610
+ <td valign="top" align="left">0.95</td>
611
+ </tr>
612
+ <tr>
613
+ <td valign="top" align="left" scope="row">Diagnosis of
614
+ stroke<break/>Ischemic Stroke<break/>TIA<break/>Hemorrhagic
615
+ stroke</td>
616
+ <td valign="top" align="left">63 (87)<break/>9 (12)<break/>1 (1)</td>
617
+ <td valign="top" align="left">33 (92)<break/>3 (8)</td>
618
+ <td valign="top" align="left">30 (81)<break/>6 (16)<break/>1 (3)</td>
619
+ <td valign="top" align="left">0.60<sup>a</sup></td>
620
+ </tr>
621
+ <tr>
622
+ <td valign="top" align="left" scope="row">Recurrent stroke</td>
623
+ <td valign="top" align="left">11 (15)</td>
624
+ <td valign="top" align="left">5 (14)</td>
625
+ <td valign="top" align="left">6 (16)</td>
626
+ <td valign="top" align="left">1.00<sup>a</sup></td>
627
+ </tr>
628
+ <tr>
629
+ <td valign="top" align="left" scope="row">Modified Rankin Scale score
630
+ &gt;&#x2009;2</td>
631
+ <td valign="top" align="left">5 (6)</td>
632
+ <td valign="top" align="left">1 (3)</td>
633
+ <td valign="top" align="left">4 (11)</td>
634
+ <td valign="top" align="left">0.36<sup>a</sup></td>
635
+ </tr>
636
+ <tr>
637
+ <td valign="top" align="left" scope="row">Antihypertensive medication
638
+ before stroke</td>
639
+ <td valign="top" align="left">39 (53)</td>
640
+ <td valign="top" align="left">15 (42)</td>
641
+ <td valign="top" align="left">24 (65)</td>
642
+ <td valign="top" align="left">0.047</td>
643
+ </tr>
644
+ <tr>
645
+ <td valign="top" align="left" scope="row">Antihypertensive medication at
646
+ discharge</td>
647
+ <td valign="top" align="left">46 (63)</td>
648
+ <td valign="top" align="left">20 (56)</td>
649
+ <td valign="top" align="left">26 (70)</td>
650
+ <td valign="top" align="left">0.19</td>
651
+ </tr>
652
+ <tr>
653
+ <td valign="top" align="left" scope="row">Cholesterol lowering
654
+ medication before stroke</td>
655
+ <td valign="top" align="left">25 (34)</td>
656
+ <td valign="top" align="left">11 (31)</td>
657
+ <td valign="top" align="left">14 (38)</td>
658
+ <td valign="top" align="left">0.51</td>
659
+ </tr>
660
+ <tr>
661
+ <td valign="top" align="left" scope="row">Cholesterol lowering
662
+ medication at discharge</td>
663
+ <td valign="top" align="left">65 (89)</td>
664
+ <td valign="top" align="left">35 (97)</td>
665
+ <td valign="top" align="left">30 (81)</td>
666
+ <td valign="top" align="left">0.03</td>
667
+ </tr>
668
+ <tr>
669
+ <td valign="top" align="left" scope="row">Diabetes at baseline</td>
670
+ <td valign="top" align="left">14 (19)</td>
671
+ <td valign="top" align="left">5 (14)</td>
672
+ <td valign="top" align="left">9 (24)</td>
673
+ <td valign="top" align="left">0.37<sup>a</sup></td>
674
+ </tr>
675
+ <tr>
676
+ <td valign="top" align="left" scope="row">Diabetes at discharge</td>
677
+ <td valign="top" align="left">16 (22)</td>
678
+ <td valign="top" align="left">6 (17)</td>
679
+ <td valign="top" align="left">10 (27)</td>
680
+ <td valign="top" align="left">0.29</td>
681
+ </tr>
682
+ <tr>
683
+ <td valign="top" align="left" scope="row">Atrial fibrillation at
684
+ baseline</td>
685
+ <td valign="top" align="left">7 (10)</td>
686
+ <td valign="top" align="left">3 (8)</td>
687
+ <td valign="top" align="left">4 (11)</td>
688
+ <td valign="top" align="left">1.00<sup>a</sup></td>
689
+ </tr>
690
+ <tr>
691
+ <td valign="top" align="left" scope="row">Atrial fibrillation at
692
+ discharge</td>
693
+ <td valign="top" align="left">12 (16)</td>
694
+ <td valign="top" align="left">6 (16)</td>
695
+ <td valign="top" align="left">6 (17)</td>
696
+ <td valign="top" align="left">1.00</td>
697
+ </tr>
698
+ <tr>
699
+ <td valign="top" align="left" scope="row">Unhealthy
700
+ dieting<sup>b</sup></td>
701
+ <td valign="top" align="left">59 (82)</td>
702
+ <td valign="top" align="left">25 (71)</td>
703
+ <td valign="top" align="left">34 (92)</td>
704
+ <td valign="top" align="left">0.03</td>
705
+ </tr>
706
+ <tr>
707
+ <td valign="top" align="left" scope="row">Current smoking</td>
708
+ <td valign="top" align="left">19 (26)</td>
709
+ <td valign="top" align="left">11 (31)</td>
710
+ <td valign="top" align="left">8 (22)</td>
711
+ <td valign="top" align="left">0.62</td>
712
+ </tr>
713
+ <tr>
714
+ <td valign="top" align="left" scope="row">Alcohol above
715
+ limits<sup>c</sup></td>
716
+ <td valign="top" align="left">23 (32)</td>
717
+ <td valign="top" align="left">12 (34)</td>
718
+ <td valign="top" align="left">11 (30)</td>
719
+ <td valign="top" align="left">0.68</td>
720
+ </tr>
721
+ <tr>
722
+ <td valign="top" align="left" scope="row">Sedentary
723
+ lifestyle<sup>d</sup></td>
724
+ <td valign="top" align="left">17 (24)</td>
725
+ <td valign="top" align="left">9 (26)</td>
726
+ <td valign="top" align="left">8 (22)</td>
727
+ <td valign="top" align="left">0.68</td>
728
+ </tr>
729
+ <tr>
730
+ <td valign="top" align="left" scope="row"
731
+ >BMI&#x2009;&#x2265;&#x2009;25</td>
732
+ <td valign="top" align="left">46 (63)</td>
733
+ <td valign="top" align="left">24 (67)</td>
734
+ <td valign="top" align="left">22 (59)</td>
735
+ <td valign="top" align="left">0.52</td>
736
+ </tr>
737
+ <tr>
738
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt"
739
+ scope="row">Self-rated health: fair, poor, or very poor</td>
740
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt">34
741
+ (47)</td>
742
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt">15
743
+ (43)</td>
744
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt">19
745
+ (51)</td>
746
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt"
747
+ >0.47</td>
748
+ </tr>
749
+ </tbody>
750
+ </table>
751
+ <table-wrap-foot>
752
+ <p>Values are expressed as frequencies (%) or as
753
+ mean&#x2009;&#x00B1;&#x2009;standard deviations</p>
754
+ <fn id="BRB3-2019-12-0787-tfn1">
755
+ <label><sup>a</sup></label>
756
+ <p>Fisher&#x2019;s exact test. <sup>b</sup> Less than 600 g of fruit and
757
+ vegetables per day, fish for dinner less than twice per week.
758
+ <sup>c</sup> More than 7 drinks per week in women/more than 14
759
+ drinks per week in men. <sup>d</sup> Less than 30 min of moderate
760
+ physical activity per day.</p>
761
+ </fn>
762
+ </table-wrap-foot>
763
+ </table-wrap>
764
+ <p>Less than 20% of patients had a baseline BP treated to target (<xref ref-type="fig"
765
+ rid="BRB3-2019-12-0787-fig-0002">Figure 2</xref>). Twenty-eight patients (78%)
766
+ in the intervention group and 29 patients (78%) in the control group had a 3-month
767
+ visit in the outpatient clinic. Here 15 patients (42%) in the intervention group had
768
+ their BP and blood cholesterol measured and so had 23 patients (62%) in the control
769
+ group. At follow up patients in both groups reported a median of two visits
770
+ including BP measurement at the general practitioner&#x00B4;s office since discharge
771
+ from hospital.</p>
772
+ <fig id="BRB3-2019-12-0787-fig-0002" position="float" fig-type="half-left">
773
+ <label>FIGURE 2</label>
774
+ <caption>
775
+ <p>Blood pressure and treatment of hypertension at baseline in 73 patients
776
+ (%)</p>
777
+ </caption>
778
+ <graphic xlink:href="BRB3-2019-12-0787-fig-0002.png"/>
779
+ </fig>
780
+ <sec id="BRB3-2019-12-0787-sec3.1">
781
+ <label>3.1</label>
782
+ <title>Primary endpoint</title>
783
+ <p>Follow up visits showed that 25 patients (69%) in the intervention group had a BP
784
+ at target versus 14 (38%) of controls
785
+ (<italic>p</italic>&#x2009;=&#x2009;0.007). In four patients (10%) in the
786
+ intervention group antihypertensive medication remained unchanged since
787
+ discharge versus 23 (62%) of controls
788
+ (<italic>p</italic>&#x2009;&lt;&#x2009;0.0001) illustrated by the differences in
789
+ BP treated to target as well as untreated hypertension in <xref ref-type="fig"
790
+ rid="BRB3-2019-12-0787-fig-0003">Figure 3</xref>.</p>
791
+ <fig id="BRB3-2019-12-0787-fig-0003" position="float" fig-type="half-left">
792
+ <label>FIGURE 3</label>
793
+ <caption>
794
+ <p>Blood pressure and treatment of hypertension at follow up in 73 patients
795
+ (%)</p>
796
+ </caption>
797
+ <graphic xlink:href="BRB3-2019-12-0787-fig-0003.png"/>
798
+ </fig>
799
+ </sec>
800
+ <sec id="BRB3-2019-12-0787-sec3.2">
801
+ <label>3.2</label>
802
+ <title>Secondary endpoints</title>
803
+ <p>Median reduction in systolic BP was 11 mm Hg (-5-19) with 14 mm Hg (IQR:
804
+ 5&#x2013;21) in the intervention group and 3 mm Hg (IQR -11-17) in the control
805
+ group (<italic>p</italic>&#x2009;=&#x2009;0.045). Median reduction in diastolic
806
+ BP was 2 mm Hg (-2-11) with 7 mm Hg (IQR -1-13) in the intervention group and 1
807
+ mm Hg (IQR -6-8) in the control group
808
+ (<italic>p</italic>&#x2009;=&#x2009;0.04).</p>
809
+ <p>There was no difference between the groups regarding LDL-cholesterol treated to
810
+ target with 32 patients (89%) at target in the intervention group versus 29
811
+ patients (78%) in the control group (<italic>p</italic>&#x2009;=&#x2009;0.21).
812
+ We found significant reductions in LDL-cholesterol in both groups, but no
813
+ difference between the groups: 1.6 (IQR: 0.4&#x2013;2.2) mmol/l in the
814
+ intervention group versus 0.8 (IQR: 0.4&#x2013;1.8) mmol/l among controls
815
+ (<italic>p</italic>&#x2009;=&#x2009;0.18).</p>
816
+ <p>In 11 patients (31%) in the intervention group cholesterol lowering medication
817
+ remained unchanged since discharge versus 29 (78%) of controls
818
+ (<italic>p</italic>&#x2009;&lt;&#x2009;0.0001).</p>
819
+ <p>The combined endpoint of both BP and LDL-cholesterol at target was achieved in 22
820
+ (61%) of patients in the intervention group and in 10 patients (27%) in the
821
+ control group (<italic>p</italic>&#x2009;=&#x2009;0.003). At the end of the
822
+ study 24 patients (68%) in the intervention group measured their BP at home
823
+ versus 14 (38%) of controls (<italic>p</italic>&#x2009;=&#x2009;0.03).</p>
824
+ <p>The only significant change in lifestyle was a reduction in current smokers by
825
+ four in the control group (<xref ref-type="table"
826
+ rid="BRB3-2019-12-0787-tbl-0002">Table 2</xref>).</p>
827
+ <table-wrap id="BRB3-2019-12-0787-tbl-0002" position="float">
828
+ <label>TABLE 2</label>
829
+ <caption>
830
+ <title>Nine months follow up of 73 patients</title>
831
+ </caption>
832
+ <table frame="hsides" rules="groups">
833
+ <col width="52.91%"/>
834
+ <col width="11.06%"/>
835
+ <col width="14.16%"/>
836
+ <col width="11.5%"/>
837
+ <col width="10.37%"/>
838
+ <thead>
839
+ <tr>
840
+ <th valign="top" align="left" scope="col"
841
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
842
+ >Characteristics</th>
843
+ <th valign="top" align="left" scope="col"
844
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
845
+ >All<break/>(<italic>n</italic>&#x2009;=&#x2009;73)</th>
846
+ <th valign="top" align="left" scope="col"
847
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
848
+ >Intervention<break/>(<italic>n</italic>&#x2009;=&#x2009;36)</th>
849
+ <th valign="top" align="left" scope="col"
850
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
851
+ >Control<break/>(<italic>n</italic>&#x2009;=&#x2009;37)</th>
852
+ <th valign="top" align="left" scope="col"
853
+ style="border-top: solid 0.50pt; border-bottom: solid 0.50pt"
854
+ >P</th>
855
+ </tr>
856
+ </thead>
857
+ <tbody>
858
+ <tr>
859
+ <td valign="top" align="left" style="border-top: solid 0.50pt"
860
+ scope="row">Systolic BP, mm Hg, mean &#x00B1;&#x2009;SD</td>
861
+ <td valign="top" align="left" style="border-top: solid 0.50pt">134
862
+ &#x00B1;&#x2009;21</td>
863
+ <td valign="top" align="left" style="border-top: solid 0.50pt">130
864
+ &#x00B1;&#x2009;17</td>
865
+ <td valign="top" align="left" style="border-top: solid 0.50pt">137
866
+ &#x00B1;&#x2009;24</td>
867
+ <td valign="top" align="left" style="border-top: solid 0.50pt"
868
+ >0.12</td>
869
+ </tr>
870
+ <tr>
871
+ <td valign="top" align="left" scope="row">Diastolic BP, mm Hg, mean
872
+ &#x00B1;&#x2009;SD</td>
873
+ <td valign="top" align="left">78 &#x00B1;&#x2009;11</td>
874
+ <td valign="top" align="left">78 &#x00B1;&#x2009;10</td>
875
+ <td valign="top" align="left">78 &#x00B1;&#x2009;12.8)</td>
876
+ <td valign="top" align="left">0.94</td>
877
+ </tr>
878
+ <tr>
879
+ <td valign="top" align="left" scope="row">Antihypertensive
880
+ medication</td>
881
+ <td valign="top" align="left">55 (75)</td>
882
+ <td valign="top" align="left">29 (81)</td>
883
+ <td valign="top" align="left">26 (70)</td>
884
+ <td valign="top" align="left">0.31</td>
885
+ </tr>
886
+ <tr>
887
+ <td valign="top" align="left" scope="row">100% compliance with AHM
888
+ (<italic>n</italic>&#x2009;=&#x2009;45)</td>
889
+ <td valign="top" align="left">38 (84)</td>
890
+ <td valign="top" align="left">23 (89)</td>
891
+ <td valign="top" align="left">15 (79)</td>
892
+ <td valign="top" align="left">0.38</td>
893
+ </tr>
894
+ <tr>
895
+ <td valign="top" align="left" scope="row">LDL-cholesterol, mmol/l
896
+ (<italic>n</italic>&#x2009;=&#x2009;72), mean
897
+ &#x00B1;&#x2009;SD</td>
898
+ <td valign="top" align="left">1.9 &#x00B1;&#x2009;0.8</td>
899
+ <td valign="top" align="left">1.9 &#x00B1;&#x2009;0.7</td>
900
+ <td valign="top" align="left">2.0 &#x00B1;&#x2009;0.8</td>
901
+ <td valign="top" align="left">0.66</td>
902
+ </tr>
903
+ <tr>
904
+ <td valign="top" align="left" scope="row">Cholesterol lowering
905
+ medication</td>
906
+ <td valign="top" align="left">64 (88)</td>
907
+ <td valign="top" align="left">32 (89)</td>
908
+ <td valign="top" align="left">32 (86)</td>
909
+ <td valign="top" align="left">0.76</td>
910
+ </tr>
911
+ <tr>
912
+ <td valign="top" align="left" scope="row">100% compliance with CLM
913
+ (<italic>n</italic>&#x2009;=&#x2009;52)</td>
914
+ <td valign="top" align="left">46 (89)</td>
915
+ <td valign="top" align="left">24 (86)</td>
916
+ <td valign="top" align="left">22 (92)</td>
917
+ <td valign="top" align="left">0.50</td>
918
+ </tr>
919
+ <tr>
920
+ <td valign="top" align="left" scope="row">Unhealthy
921
+ dieting<sup>b</sup></td>
922
+ <td valign="top" align="left">59 (81)</td>
923
+ <td valign="top" align="left">26 (72)</td>
924
+ <td valign="top" align="left">33 (89)</td>
925
+ <td valign="top" align="left">0.76</td>
926
+ </tr>
927
+ <tr>
928
+ <td valign="top" align="left" scope="row">Current smoker</td>
929
+ <td valign="top" align="left">15 (21)</td>
930
+ <td valign="top" align="left">11 (31)</td>
931
+ <td valign="top" align="left">4 (11)</td>
932
+ <td valign="top" align="left">0.046<sup>a</sup></td>
933
+ </tr>
934
+ <tr>
935
+ <td valign="top" align="left" scope="row"
936
+ >Alcohol&#x2009;&gt;&#x2009;limits<sup>c</sup></td>
937
+ <td valign="top" align="left">20 (27)</td>
938
+ <td valign="top" align="left">11 (31)</td>
939
+ <td valign="top" align="left">9 (24)</td>
940
+ <td valign="top" align="left">0.55</td>
941
+ </tr>
942
+ <tr>
943
+ <td valign="top" align="left" scope="row">Sedentary
944
+ lifestyle<sup>d</sup></td>
945
+ <td valign="top" align="left">16 (22)</td>
946
+ <td valign="top" align="left">7 (20)</td>
947
+ <td valign="top" align="left">9 (24)</td>
948
+ <td valign="top" align="left">0.66</td>
949
+ </tr>
950
+ <tr>
951
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt"
952
+ scope="row">BMI&#x2009;&#x2265;&#x2009;25</td>
953
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt">43
954
+ (59)</td>
955
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt">21
956
+ (58)</td>
957
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt">22
958
+ (60)</td>
959
+ <td valign="top" align="left" style="border-bottom: solid 0.50pt"
960
+ >0.92</td>
961
+ </tr>
962
+ </tbody>
963
+ </table>
964
+ <table-wrap-foot>
965
+ <p>Values are expressed as frequencies (%) or as
966
+ mean&#x2009;&#x00B1;&#x2009;standard deviations.&#x2028;Abbreviations:
967
+ AHM, antihypertensive medication; CLM, cholesterol lowering
968
+ medication.</p>
969
+ <fn id="BRB3-2019-12-0787-tfn2">
970
+ <label><sup>a</sup></label>
971
+ <p>Fisher&#x2019;s exact test. <sup>b</sup> Less than 600 g of fruit and
972
+ vegetables per day, fish for dinner less than twice per week.
973
+ <sup>c</sup> More than 7 drinks per week in women/more than 14
974
+ drinks per week in men. <sup>d</sup> Less than 30 min of moderate
975
+ physical activity per day.</p>
976
+ </fn>
977
+ <p/>
978
+ </table-wrap-foot>
979
+ </table-wrap>
980
+ <p>Regarding vascular complications and death, we found 32 events in 22 patients
981
+ after a median of 65 months. Median time to first event was 26 months (IQR:
982
+ 4&#x2013;49) with a median of 44 months (IQR: 11&#x2013;49) in the intervention
983
+ group and 19 months (IQR: 4&#x2013;37) in the control group
984
+ (<italic>p</italic>&#x2009;=&#x2009;0.32). All in all, we found 11 events in
985
+ nine patients in the intervention group: two recurrent strokes, three cases of
986
+ TIA, and six patients died versus 21 events in 13 patients in the control group:
987
+ seven recurrent strokes, five cases of TIA, one MI, and seven patients died
988
+ (<italic>p</italic>&#x2009;=&#x2009;0.49).</p>
989
+ </sec>
990
+ </sec>
991
+ <sec id="BRB3-2019-12-0787-sec4" sec-type="discussion">
992
+ <label>4</label>
993
+ <title>DISCUSSION</title>
994
+ <p>In this randomized clinical trial, a larger proportion of patients in the
995
+ intervention group compared to controls had BP within the above-mentioned limits and
996
+ the study fulfilled the aim of the primary endpoint.</p>
997
+ <p>A systematic review of interventions aimed at modifiable risk factor control for
998
+ secondary prevention of stroke revealed improvement in achieving BP target. <xref
999
+ ref-type="bibr" rid="BRB3-2019-12-0787-bib-0022"><sup>22</sup></xref> However,
1000
+ as opposed to our study the review showed no significant change in systolic og
1001
+ diastolic BP.</p>
1002
+ <p>In a study of integrated care with five prearranged visits to patients&#x2019;
1003
+ general practitioner versus usual care systolic BP at target set to 140 mm Hg was
1004
+ found in 75% versus 58% at 12-month follow up. <xref ref-type="bibr"
1005
+ rid="BRB3-2019-12-0787-bib-0019"><sup>19</sup></xref> We set individual targets
1006
+ for BP according to patients&#x2019; type of stroke, comorbidities and age. This is
1007
+ well in line with recommendations given by European Society of Hypertension, <xref
1008
+ ref-type="bibr" rid="BRB3-2019-12-0787-bib-0023"><sup>23</sup></xref> but as
1009
+ stated by Boan et al., not quite in accordance with international stroke guidelines.
1010
+ <xref ref-type="bibr" rid="BRB3-2019-12-0787-bib-0024"><sup>24</sup></xref></p>
1011
+ <p>In a study where patients with minor stroke were randomized to six clinic visits by a
1012
+ pharmacist (intervention) or by a nurse (active control) aiming at treating both BP
1013
+ and LDL-cholesterol to target, 43% of patients in the pharmacist-led clinic met
1014
+ those two targets and so did 31% in the nurse-led clinic. <xref ref-type="bibr"
1015
+ rid="BRB3-2019-12-0787-bib-0025"><sup>25</sup></xref> In our study this combined
1016
+ endpoint was met in 22 (61%) of patients in the intervention group. Regarding BP in
1017
+ control 80% of patients in the pharmacist led clinic had systolic BP in control
1018
+ after six months versus 90% in the nurse led clinic. This is a far greater
1019
+ proportion than the 69% in our study. However, almost two thirds of patients had a
1020
+ baseline BP within the limits. The opposite was the case in our study with two
1021
+ thirds presenting with elevated BP. Both studies show that a dedicated follow up
1022
+ with stepwise escalation of preventive medication may be the way to reach the
1023
+ targets of the two important risk factors for recurrent stroke. In both studies
1024
+ five-six visits were needed, which is far beyond our usual treatment. However,
1025
+ despite visits to the outpatient clinic as well as to the general practitioner the
1026
+ proportion of patients with unchanged medication since discharge in the control
1027
+ group illustrate the necessity of frequent visits to a dedicated preventive
1028
+ facility. Considering the preventive effect of BP lowering, and - though
1029
+ insignificant - the difference in time to first event as well as the smaller
1030
+ proportion of events in the intervention group as found in our study, it may be well
1031
+ worth the time and resources for patients, their relatives and society.</p>
1032
+ <sec id="BRB3-2019-12-0787-sec4.1">
1033
+ <label>4.1</label>
1034
+ <title>Strengths and limitations</title>
1035
+ <p>Our study has some limitations. Most participants had a minor stroke and patients
1036
+ had to be independent and without severe cognitive deficits, which is not
1037
+ representative of a general stroke population. With only 73 participants caution
1038
+ is called for in the drawing of conclusions from the results. Nonetheless, we
1039
+ decided to reorganize the outpatient clinic of our stroke unit as of October
1040
+ 2014 implementing strategies of the present study.</p>
1041
+ <p>The strength of the study is the individual target for BP taking into account the
1042
+ diagnosis of stroke as well as important comorbidity as recommended by Boan et
1043
+ al. <xref ref-type="bibr" rid="BRB3-2019-12-0787-bib-0024"><sup>24</sup></xref>
1044
+ Five-year follow up on vascular complications and death is another important
1045
+ advantage.</p>
1046
+ </sec>
1047
+ </sec>
1048
+ <sec id="BRB3-2019-12-0787-sec5" sec-type="conclusions">
1049
+ <label>5</label>
1050
+ <title>CONCLUSIONS</title>
1051
+ <p>In conclusion, the feasibility study has demonstrated that timely follow up of stroke
1052
+ patients in a dedicated preventive outpatient clinic may result in BP and
1053
+ cholesterol treated to target in most patients. To some extent it may postpone time
1054
+ to stroke recurrence, MI and death.</p>
1055
+ </sec>
1056
+ </body>
1057
+ <back>
1058
+ <ack>
1059
+ <title>ACKNOWLEDGMENTS</title>
1060
+ <p>None.<xref ref-type="bibr" rid="BRB3-2019-12-0787-bib-0021"><sup>21</sup></xref></p>
1061
+ </ack>
1062
+ <fn-group>
1063
+ <fn fn-type="conflict">
1064
+ <p content-type="fn-title">CONFLICT OF INTEREST</p>
1065
+ <p>None.</p>
1066
+ </fn>
1067
+ </fn-group>
1068
+ <sec sec-type="data-availability">
1069
+ <title>DATA AVAILABILITY</title>
1070
+ <p>The data that support the findings of this study are not available due to national
1071
+ privacy or ethical restrictions.</p>
1072
+ </sec>
1073
+ <ref-list>
1074
+ <title>Reference List</title>
1075
+ <ref id="BRB3-2019-12-0787-bib-0001">
1076
+ <label>1</label>
1077
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1078
+ ><string-name><surname>Wahlgren</surname>,
1079
+ <given-names>N.</given-names></string-name>,
1080
+ <string-name><surname>Ahmed</surname>,
1081
+ <given-names>N.</given-names></string-name>,
1082
+ <string-name><surname>Eriksson</surname>,
1083
+ <given-names>N.</given-names></string-name>,
1084
+ <string-name><surname>Aichner</surname>,
1085
+ <given-names>F.</given-names></string-name>,
1086
+ <string-name><surname>Bluhmki</surname>,
1087
+ <given-names>E.</given-names></string-name>,
1088
+ <string-name><surname>D&#x00E1;valos</surname>,
1089
+ <given-names>A.</given-names></string-name>, <etal>. . .</etal>
1090
+ <string-name><surname>Vanhooren</surname>,
1091
+ <given-names>G.</given-names></string-name>, &amp; the <collab>Safe
1092
+ Implementation of Thrombolysis in Stroke-MOnitoring STudy
1093
+ Investigators</collab></person-group>. (<year>2008</year>).
1094
+ <article-title>Multivariable analysis of outcome predictors and adjustment
1095
+ of main outcome results to baseline data profile in randomized controlled
1096
+ trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy
1097
+ (SITS-MOST).</article-title>
1098
+ <source>Stroke</source>, <volume>39</volume>,
1099
+ <fpage>3316</fpage>&#x2013;<lpage>3322</lpage>. <pub-id pub-id-type="doi"
1100
+ >https://doi.org/10.1161/STROKEAHA.107.510768</pub-id><pub-id
1101
+ pub-id-type="pmid">18927461</pub-id></mixed-citation>
1102
+ </ref>
1103
+ <ref id="BRB3-2019-12-0787-bib-0002">
1104
+ <label>2</label>
1105
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1106
+ ><string-name><surname>Wahlgren</surname>,
1107
+ <given-names>N.</given-names></string-name></person-group>
1108
+ (<year>2009</year>). <article-title>Systemic thrombolysis in clinical
1109
+ practice: What have we learned after the Safe Implementation of Thrombolysis
1110
+ in Stroke Monitoring Study?</article-title>
1111
+ <source>Cerebrovascular Diseases (Basel, Switzerland)</source>,
1112
+ <volume>27</volume>(<supplement>Suppl 1</supplement>),
1113
+ <fpage>168</fpage>&#x2013;<lpage>176</lpage>. <pub-id pub-id-type="doi"
1114
+ >https://doi.org/10.1159/000200456</pub-id><pub-id pub-id-type="pmid"
1115
+ >19342848</pub-id></mixed-citation>
1116
+ </ref>
1117
+ <ref id="BRB3-2019-12-0787-bib-0003">
1118
+ <label>3</label>
1119
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1120
+ ><string-name><surname>Thorvaldsen</surname>,
1121
+ <given-names>P.</given-names></string-name>,
1122
+ <string-name><surname>Davidsen</surname>,
1123
+ <given-names>M.</given-names></string-name>,
1124
+ <string-name><surname>Br&#x00F8;nnum-Hansen</surname>,
1125
+ <given-names>H.</given-names></string-name>, &amp;
1126
+ <string-name><surname>Schroll</surname>,
1127
+ <given-names>M.</given-names></string-name></person-group>
1128
+ (<year>1999</year>). <article-title>Stable stroke occurrence despite
1129
+ incidence reduction in an aging population: Stroke trends in the danish
1130
+ monitoring trends and determinants in cardiovascular disease (MONICA)
1131
+ population.</article-title>
1132
+ <source>Stroke</source>, <volume>30</volume>,
1133
+ <fpage>2529</fpage>&#x2013;<lpage>2534</lpage>. <pub-id pub-id-type="doi"
1134
+ >https://doi.org/10.1161/01.STR.30.12.2529</pub-id><pub-id
1135
+ pub-id-type="pmid">10582973</pub-id></mixed-citation>
1136
+ </ref>
1137
+ <ref id="BRB3-2019-12-0787-bib-0004">
1138
+ <label>4</label>
1139
+ <?AuthorQuery id="Q4" queryText="eXtyles has not updated the authors because of a name mismatch. Please compare &quot;J&#x00F8;rgensen&quot; with &quot;Jerrgensen&quot;. The CrossRef authors are Jerrgensen, H. S., Nakayama, H., Reith, J., Raaschou, H. O., &amp; Olsen, T. S.. (Ref. 4 &quot;J&#x00F8;rgensen, Nakayama, Reith, Raaschou, Olsen, 1997&quot;)"?>
1140
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1141
+ ><string-name><surname>J&#x00F8;rgensen</surname>, <given-names>H.
1142
+ S.</given-names></string-name>,
1143
+ <string-name><surname>Nakayama</surname>,
1144
+ <given-names>H.</given-names></string-name>,
1145
+ <string-name><surname>Reith</surname>,
1146
+ <given-names>J.</given-names></string-name>,
1147
+ <string-name><surname>Raaschou</surname>, <given-names>H.
1148
+ O.</given-names></string-name>, &amp;
1149
+ <string-name><surname>Olsen</surname>, <given-names>T.
1150
+ S.</given-names></string-name></person-group> (<year>1997</year>).
1151
+ <article-title>Stroke recurrence: Predictors, severity, and prognosis. The
1152
+ Copenhagen Stroke Study.</article-title>
1153
+ <source>Neurology</source>, <volume>48</volume>,
1154
+ <fpage>891</fpage>&#x2013;<lpage>895</lpage>. <pub-id pub-id-type="doi"
1155
+ >https://doi.org/10.1212/WNL.48.4.891</pub-id><pub-id pub-id-type="pmid"
1156
+ >9109873</pub-id></mixed-citation>
1157
+ </ref>
1158
+ <ref id="BRB3-2019-12-0787-bib-0005">
1159
+ <label>5</label>
1160
+ <mixed-citation specific-use="unstructured-citation" publication-type="other">Danish Stroke Registry. Danish Stroke
1161
+ Registry, annual report 2011. 2011. Ref Type: Generic.</mixed-citation>
1162
+ </ref>
1163
+ <ref id="BRB3-2019-12-0787-bib-0006">
1164
+ <label>6</label>
1165
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1166
+ ><string-name><surname>Friday</surname>,
1167
+ <given-names>G.</given-names></string-name>,
1168
+ <string-name><surname>Alter</surname>,
1169
+ <given-names>M.</given-names></string-name>, &amp;
1170
+ <string-name><surname>Lai</surname>, <given-names>S.
1171
+ M.</given-names></string-name></person-group> (<year>2002</year>).
1172
+ <article-title>Control of hypertension and risk of stroke
1173
+ recurrence.</article-title>
1174
+ <source>Stroke</source>, <volume>33</volume>,
1175
+ <fpage>2652</fpage>&#x2013;<lpage>2657</lpage>. <pub-id pub-id-type="doi"
1176
+ >https://doi.org/10.1161/01.STR.0000033929.62136.6F</pub-id><pub-id
1177
+ pub-id-type="pmid">12411656</pub-id></mixed-citation>
1178
+ </ref>
1179
+ <ref id="BRB3-2019-12-0787-bib-0007">
1180
+ <label>7</label>
1181
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1182
+ ><string-name><surname>Lai</surname>, <given-names>S.
1183
+ M.</given-names></string-name>,
1184
+ <string-name><surname>Alter</surname>,
1185
+ <given-names>M.</given-names></string-name>,
1186
+ <string-name><surname>Friday</surname>,
1187
+ <given-names>G.</given-names></string-name>, &amp;
1188
+ <string-name><surname>Sobel</surname>,
1189
+ <given-names>E.</given-names></string-name></person-group>
1190
+ (<year>1994</year>). <article-title>A multifactorial analysis of risk
1191
+ factors for recurrence of ischemic stroke.</article-title>
1192
+ <source>Stroke</source>, <volume>25</volume>,
1193
+ <fpage>958</fpage>&#x2013;<lpage>962</lpage>. <pub-id pub-id-type="doi"
1194
+ >https://doi.org/10.1161/01.STR.25.5.958</pub-id><pub-id pub-id-type="pmid"
1195
+ >8165690</pub-id></mixed-citation>
1196
+ </ref>
1197
+ <ref id="BRB3-2019-12-0787-bib-0008">
1198
+ <label>8</label>
1199
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1200
+ ><string-name><surname>Prencipe</surname>,
1201
+ <given-names>M.</given-names></string-name>,
1202
+ <string-name><surname>Culasso</surname>,
1203
+ <given-names>F.</given-names></string-name>,
1204
+ <string-name><surname>Rasura</surname>,
1205
+ <given-names>M.</given-names></string-name>,
1206
+ <string-name><surname>Anzini</surname>,
1207
+ <given-names>A.</given-names></string-name>,
1208
+ <string-name><surname>Beccia</surname>,
1209
+ <given-names>M.</given-names></string-name>,
1210
+ <string-name><surname>Cao</surname>,
1211
+ <given-names>M.</given-names></string-name>, <etal>. . .</etal>
1212
+ <string-name><surname>Fieschi</surname>,
1213
+ <given-names>C.</given-names></string-name></person-group>
1214
+ (<year>1998</year>). <article-title>Long-term prognosis after a minor
1215
+ stroke: 10-year mortality and major stroke recurrence rates in a
1216
+ hospital-based cohort.</article-title>
1217
+ <source>Stroke</source>, <volume>29</volume>,
1218
+ <fpage>126</fpage>&#x2013;<lpage>132</lpage>. <pub-id pub-id-type="doi"
1219
+ >https://doi.org/10.1161/01.STR.29.1.126</pub-id><pub-id pub-id-type="pmid"
1220
+ >9445340</pub-id></mixed-citation>
1221
+ </ref>
1222
+ <ref id="BRB3-2019-12-0787-bib-0009">
1223
+ <label>9</label>
1224
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1225
+ ><string-name><surname>Rashid</surname>,
1226
+ <given-names>P.</given-names></string-name>,
1227
+ <string-name><surname>Leonardi-Bee</surname>,
1228
+ <given-names>J.</given-names></string-name>, &amp;
1229
+ <string-name><surname>Bath</surname>,
1230
+ <given-names>P.</given-names></string-name></person-group>
1231
+ (<year>2003</year>). <article-title>Blood pressure reduction and secondary
1232
+ prevention of stroke and other vascular events: A systematic
1233
+ review.</article-title>
1234
+ <source>Stroke</source>, <volume>34</volume>,
1235
+ <fpage>2741</fpage>&#x2013;<lpage>2748</lpage>. <pub-id pub-id-type="doi"
1236
+ >https://doi.org/10.1161/01.STR.0000092488.40085.15</pub-id><pub-id
1237
+ pub-id-type="pmid">14576382</pub-id></mixed-citation>
1238
+ </ref>
1239
+ <ref id="BRB3-2019-12-0787-bib-0010">
1240
+ <label>10</label>
1241
+ <?AuthorQuery id="Q5" queryText="eXtyles has not updated this reference because the authors returned by CrossRef are invalid: Girot, M., Mackowiak-Cordoliani, M.-A., Deplanque, D., H&#xFFFD;non, H., Lucas, C., &amp; Leys, D. (2005). Secondary prevention after ischemic stroke. Journal of Neurology, <italic>252</italic>, 14&#x2013;20. (Ref. 10 &quot;Girot, Mackowiak-Cordoliani, Deplanque, H&#x00E9;non, Lucas, Leys, 2005&quot;)"?>
1242
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1243
+ ><string-name><surname>Girot</surname>,
1244
+ <given-names>M.</given-names></string-name>,
1245
+ <string-name><surname>Mackowiak-Cordoliani</surname>,
1246
+ <given-names>M. A.</given-names></string-name>,
1247
+ <string-name><surname>Deplanque</surname>,
1248
+ <given-names>D.</given-names></string-name>,
1249
+ <string-name><surname>H&#x00E9;non</surname>,
1250
+ <given-names>H.</given-names></string-name>,
1251
+ <string-name><surname>Lucas</surname>,
1252
+ <given-names>C.</given-names></string-name>, &amp;
1253
+ <string-name><surname>Leys</surname>,
1254
+ <given-names>D.</given-names></string-name></person-group>
1255
+ (<year>2005</year>). <article-title>Secondary prevention after ischemic
1256
+ stroke. Evolution over time in practice.</article-title>
1257
+ <source>Journal of Neurology</source>, <volume>252</volume>,
1258
+ <fpage>14</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi"
1259
+ >https://doi.org/10.1007/s00415-005-0591-8</pub-id><pub-id
1260
+ pub-id-type="pmid">15654550</pub-id></mixed-citation>
1261
+ </ref>
1262
+ <ref id="BRB3-2019-12-0787-bib-0011">
1263
+ <label>11</label>
1264
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1265
+ ><string-name><surname>Johnson</surname>,
1266
+ <given-names>P.</given-names></string-name>,
1267
+ <string-name><surname>Rosewell</surname>,
1268
+ <given-names>M.</given-names></string-name>, &amp;
1269
+ <string-name><surname>James</surname>, <given-names>M.
1270
+ A.</given-names></string-name></person-group> (<year>2007</year>).
1271
+ <article-title>How good is the management of vascular risk after stroke,
1272
+ transient ischaemic attack or carotid endarterectomy?</article-title>
1273
+ <source>Cerebrovascular Diseases (Basel, Switzerland)</source>,
1274
+ <volume>23</volume>, <fpage>156</fpage>&#x2013;<lpage>161</lpage>. <pub-id
1275
+ pub-id-type="doi">https://doi.org/10.1159/000097053</pub-id><pub-id
1276
+ pub-id-type="pmid">17124397</pub-id></mixed-citation>
1277
+ </ref>
1278
+ <ref id="BRB3-2019-12-0787-bib-0012">
1279
+ <label>12</label>
1280
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1281
+ ><string-name><surname>Paul</surname>, <given-names>S.
1282
+ L.</given-names></string-name>, &amp;
1283
+ <string-name><surname>Thrift</surname>, <given-names>A.
1284
+ G.</given-names></string-name></person-group> (<year>2006</year>).
1285
+ <article-title>Control of hypertension 5 years after stroke in the North
1286
+ East Melbourne Stroke Incidence Study.</article-title>
1287
+ <source>Hypertension</source>, <volume>48</volume>,
1288
+ <fpage>260</fpage>&#x2013;<lpage>265</lpage>. <pub-id pub-id-type="doi"
1289
+ >https://doi.org/10.1161/01.HYP.0000230610.81947.04</pub-id><pub-id
1290
+ pub-id-type="pmid">16785330</pub-id></mixed-citation>
1291
+ </ref>
1292
+ <ref id="BRB3-2019-12-0787-bib-0013">
1293
+ <label>13</label>
1294
+ <mixed-citation publication-type="journal">
1295
+ <?AuthorQuery id="Q6" queryText="Medline reports the journal title should be &quot;International journal of stroke : official journal of the International Stroke Society or Int J Stroke&quot;, not &quot;International Journal of Stroke&quot;. (Ref. 13 &quot;Hornnes, Larsen, Boysen, 2010&quot;)"?>
1296
+ <person-group person-group-type="author"
1297
+ ><string-name><surname>Hornnes</surname>,
1298
+ <given-names>N.</given-names></string-name>,
1299
+ <string-name><surname>Larsen</surname>,
1300
+ <given-names>K.</given-names></string-name>, &amp;
1301
+ <string-name><surname>Boysen</surname>,
1302
+ <given-names>G.</given-names></string-name></person-group>
1303
+ (<year>2010</year>). <article-title>Little change of modifiable risk factors
1304
+ 1 year after stroke: A pilot study.</article-title>
1305
+ <source>International Journal of Stroke</source>, <volume>5</volume>,
1306
+ <fpage>157</fpage>&#x2013;<lpage>162</lpage>. <pub-id pub-id-type="doi"
1307
+ >https://doi.org/10.1111/j.1747-4949.2010.00424.x</pub-id><pub-id
1308
+ pub-id-type="pmid">20536611</pub-id></mixed-citation>
1309
+ </ref>
1310
+ <ref id="BRB3-2019-12-0787-bib-0014">
1311
+ <label>14</label>
1312
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1313
+ ><string-name><surname>Adie</surname>,
1314
+ <given-names>K.</given-names></string-name>, &amp;
1315
+ <string-name><surname>James</surname>, <given-names>M.
1316
+ A.</given-names></string-name></person-group> (<year>2010</year>).
1317
+ <article-title>Does telephone follow-up improve blood pressure after minor
1318
+ stroke or TIA?</article-title>
1319
+ <source>Age and Ageing</source>, <volume>39</volume>,
1320
+ <fpage>598</fpage>&#x2013;<lpage>603</lpage>. <pub-id pub-id-type="doi"
1321
+ >https://doi.org/10.1093/ageing/afq085</pub-id><pub-id pub-id-type="pmid"
1322
+ >20667838</pub-id></mixed-citation>
1323
+ </ref>
1324
+ <ref id="BRB3-2019-12-0787-bib-0015">
1325
+ <label>15</label>
1326
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1327
+ ><string-name><surname>Chiu</surname>, <given-names>C.
1328
+ C.</given-names></string-name>, <string-name><surname>Wu</surname>,
1329
+ <given-names>S. S.</given-names></string-name>,
1330
+ <string-name><surname>Lee</surname>, <given-names>P.
1331
+ Y.</given-names></string-name>,
1332
+ <string-name><surname>Huang</surname>, <given-names>Y.
1333
+ C.</given-names></string-name>, <string-name><surname>Tan</surname>,
1334
+ <given-names>T. Y.</given-names></string-name>, &amp;
1335
+ <string-name><surname>Chang</surname>, <given-names>K.
1336
+ C.</given-names></string-name></person-group> (<year>2008</year>).
1337
+ <article-title>Control of modifiable risk factors in ischemic stroke
1338
+ outpatients by pharmacist intervention: An equal allocation stratified
1339
+ randomized study.</article-title>
1340
+ <source>Journal of Clinical Pharmacy and Therapeutics</source>,
1341
+ <volume>33</volume>, <fpage>529</fpage>&#x2013;<lpage>535</lpage>. <pub-id
1342
+ pub-id-type="doi"
1343
+ >https://doi.org/10.1111/j.1365-2710.2008.00940.x</pub-id><pub-id
1344
+ pub-id-type="pmid">18834368</pub-id></mixed-citation>
1345
+ </ref>
1346
+ <ref id="BRB3-2019-12-0787-bib-0016">
1347
+ <label>16</label>
1348
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1349
+ ><string-name><surname>Ellis</surname>,
1350
+ <given-names>G.</given-names></string-name>,
1351
+ <string-name><surname>Rodger</surname>,
1352
+ <given-names>J.</given-names></string-name>,
1353
+ <string-name><surname>McAlpine</surname>,
1354
+ <given-names>C.</given-names></string-name>, &amp;
1355
+ <string-name><surname>Langhorne</surname>,
1356
+ <given-names>P.</given-names></string-name></person-group>
1357
+ (<year>2005</year>). <article-title>The impact of stroke nurse specialist
1358
+ input on risk factor modification: A randomised controlled
1359
+ trial.</article-title>
1360
+ <source>Age and Ageing</source>, <volume>34</volume>,
1361
+ <fpage>389</fpage>&#x2013;<lpage>392</lpage>. <pub-id pub-id-type="doi"
1362
+ >https://doi.org/10.1093/ageing/afi075</pub-id><pub-id pub-id-type="pmid"
1363
+ >15955759</pub-id></mixed-citation>
1364
+ </ref>
1365
+ <ref id="BRB3-2019-12-0787-bib-0017">
1366
+ <label>17</label>
1367
+ <?AuthorQuery id="Q7" queryText="Medline reports the journal title should be &quot;Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association or J Stroke Cerebrovasc Dis&quot;, not &quot;Journal of Stroke and Cerebrovascular Diseases&quot;. (Ref. 17 &quot;Hornnes, Larsen, Boysen, 2011&quot;)"?>
1368
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1369
+ ><string-name><surname>Hornnes</surname>,
1370
+ <given-names>N.</given-names></string-name>,
1371
+ <string-name><surname>Larsen</surname>,
1372
+ <given-names>K.</given-names></string-name>, &amp;
1373
+ <string-name><surname>Boysen</surname>,
1374
+ <given-names>G.</given-names></string-name></person-group>
1375
+ (<year>2011</year>). <article-title>Blood pressure 1 year after stroke: The
1376
+ need to optimize secondary prevention.</article-title>
1377
+ <source>Journal of Stroke and Cerebrovascular Diseases</source>,
1378
+ <volume>20</volume>, <fpage>16</fpage>&#x2013;<lpage>23</lpage>. <pub-id
1379
+ pub-id-type="doi"
1380
+ >https://doi.org/10.1016/j.jstrokecerebrovasdis.2009.10.002</pub-id><pub-id
1381
+ pub-id-type="pmid">21187254</pub-id></mixed-citation>
1382
+ </ref>
1383
+ <ref id="BRB3-2019-12-0787-bib-0018">
1384
+ <label>18</label>
1385
+ <?AuthorQuery id="Q8" queryText="CrossRef reports the first page should be &quot;NA&quot;, not &quot;579&quot;. (Ref. 18 &quot;Johnston, Sidney, Hills, Grosvenor, Klingman, Bernstein, Levin, 2010&quot;)"?>
1386
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1387
+ ><string-name><surname>Johnston</surname>, <given-names>S.
1388
+ C.</given-names></string-name>,
1389
+ <string-name><surname>Sidney</surname>,
1390
+ <given-names>S.</given-names></string-name>,
1391
+ <string-name><surname>Hills</surname>, <given-names>N.
1392
+ K.</given-names></string-name>,
1393
+ <string-name><surname>Grosvenor</surname>,
1394
+ <given-names>D.</given-names></string-name>,
1395
+ <string-name><surname>Klingman</surname>, <given-names>J.
1396
+ G.</given-names></string-name>,
1397
+ <string-name><surname>Bernstein</surname>,
1398
+ <given-names>A.</given-names></string-name>, &amp;
1399
+ <string-name><surname>Levin</surname>,
1400
+ <given-names>E.</given-names></string-name></person-group>
1401
+ (<year>2010</year>). <article-title>Standardized discharge orders after
1402
+ stroke: Results of the quality improvement in stroke prevention (QUISP)
1403
+ cluster randomized trial.</article-title>
1404
+ <source>Annals of Neurology</source>, <volume>67</volume>,
1405
+ <fpage>579</fpage>&#x2013;<lpage>589</lpage>. <pub-id pub-id-type="doi"
1406
+ >https://doi.org/10.1002/ana.22019</pub-id><pub-id pub-id-type="pmid"
1407
+ >20437555</pub-id></mixed-citation>
1408
+ </ref>
1409
+ <ref id="BRB3-2019-12-0787-bib-0019">
1410
+ <label>19</label>
1411
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1412
+ ><string-name><surname>Joubert</surname>,
1413
+ <given-names>J.</given-names></string-name>,
1414
+ <string-name><surname>Reid</surname>,
1415
+ <given-names>C.</given-names></string-name>,
1416
+ <string-name><surname>Barton</surname>,
1417
+ <given-names>D.</given-names></string-name>,
1418
+ <string-name><surname>Cumming</surname>,
1419
+ <given-names>T.</given-names></string-name>,
1420
+ <string-name><surname>McLean</surname>,
1421
+ <given-names>A.</given-names></string-name>,
1422
+ <string-name><surname>Joubert</surname>,
1423
+ <given-names>L.</given-names></string-name>, <etal>. . .</etal>
1424
+ <string-name><surname>Davis</surname>,
1425
+ <given-names>S.</given-names></string-name></person-group>
1426
+ (<year>2009</year>). <article-title>Integrated care improves risk-factor
1427
+ modification after stroke: Initial results of the Integrated Care for the
1428
+ Reduction of Secondary Stroke model.</article-title>
1429
+ <source>Journal of Neurology, Neurosurgery, and Psychiatry</source>,
1430
+ <volume>80</volume>, <fpage>279</fpage>&#x2013;<lpage>284</lpage>. <pub-id
1431
+ pub-id-type="doi">https://doi.org/10.1136/jnnp.2008.148122</pub-id><pub-id
1432
+ pub-id-type="pmid">19010943</pub-id></mixed-citation>
1433
+ </ref>
1434
+ <ref id="BRB3-2019-12-0787-bib-0020">
1435
+ <label>20</label>
1436
+ <?AuthorQuery id="Q9" queryText="Medline reports multiple listings for this reference. Please check the reference for accuracy. (Ref. 20 &quot;Fahey, Schroeder, Ebrahim, 2006&quot;)"?>
1437
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1438
+ ><string-name><surname>Fahey</surname>,
1439
+ <given-names>T.</given-names></string-name>,
1440
+ <string-name><surname>Schroeder</surname>,
1441
+ <given-names>K.</given-names></string-name>, &amp;
1442
+ <string-name><surname>Ebrahim</surname>,
1443
+ <given-names>S.</given-names></string-name></person-group>
1444
+ (<year>2006</year>). <article-title>Interventions used to improve control of
1445
+ blood pressure in patients with hypertension.</article-title>
1446
+ <source>Cochrane Database of Systematic Reviews</source>,
1447
+ <elocation-id>CD005182</elocation-id>.</mixed-citation>
1448
+ </ref>
1449
+ <ref id="BRB3-2019-12-0787-bib-0021">
1450
+ <label>21</label>
1451
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1452
+ ><string-name><surname>Furie</surname>, <given-names>K.
1453
+ L.</given-names></string-name>,
1454
+ <string-name><surname>Kasner</surname>, <given-names>S.
1455
+ E.</given-names></string-name>,
1456
+ <string-name><surname>Adams</surname>, <given-names>R.
1457
+ J.</given-names></string-name>,
1458
+ <string-name><surname>Albers</surname>, <given-names>G.
1459
+ W.</given-names></string-name>,
1460
+ <string-name><surname>Bush</surname>, <given-names>R.
1461
+ L.</given-names></string-name>, <string-name><surname>Fagan</surname>,
1462
+ <given-names>S. C.</given-names></string-name>, <etal>. . .</etal>
1463
+ <string-name><surname>Wentworth</surname>,
1464
+ <given-names>D.</given-names></string-name>, &amp; the <collab>American
1465
+ Heart Association Stroke Council, Council on Cardiovascular Nursing,
1466
+ Council on Clinical Cardiology, and Interdisciplinary Council on Quality
1467
+ of Care and Outcomes Research</collab></person-group>.
1468
+ (<year>2011</year>). <article-title>Guidelines for the prevention of stroke
1469
+ in patients with stroke or transient ischemic attack: A guideline for
1470
+ healthcare professionals from the american heart association/american stroke
1471
+ association.</article-title>
1472
+ <source><italic>Stroke</italic></source>, <volume>42</volume>,
1473
+ <fpage>227</fpage>&#x2013;<lpage>276</lpage>. <pub-id pub-id-type="doi"
1474
+ >https://doi.org/10.1161/STR.0b013e3181f7d043</pub-id><pub-id
1475
+ pub-id-type="pmid">20966421</pub-id></mixed-citation>
1476
+ </ref>
1477
+ <ref id="BRB3-2019-12-0787-bib-0022">
1478
+ <label>22</label>
1479
+ <?AuthorQuery id="Q10" queryText="Medline reports the journal title should be &quot;The Cochrane database of systematic reviews or Cochrane Database Syst Rev&quot;, not &quot;Cochrane Database of Systematic Reviews&quot;. (Ref. 22 &quot;Bridgwood, Lager, Mistri, Khunti, Wilson, Modi, 2018&quot;)"?>
1480
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1481
+ ><string-name><surname>Bridgwood</surname>,
1482
+ <given-names>B.</given-names></string-name>,
1483
+ <string-name><surname>Lager</surname>, <given-names>K.
1484
+ E.</given-names></string-name>,
1485
+ <string-name><surname>Mistri</surname>, <given-names>A.
1486
+ K.</given-names></string-name>,
1487
+ <string-name><surname>Khunti</surname>,
1488
+ <given-names>K.</given-names></string-name>,
1489
+ <string-name><surname>Wilson</surname>, <given-names>A.
1490
+ D.</given-names></string-name>, &amp;
1491
+ <string-name><surname>Modi</surname>,
1492
+ <given-names>P.</given-names></string-name></person-group>
1493
+ (<year>2018</year>). <article-title>Interventions for improving modifiable
1494
+ risk factor control in the secondary prevention of stroke.</article-title>
1495
+ <source>Cochrane Database of Systematic Reviews</source>, <volume>5</volume>,
1496
+ <elocation-id>CD009103</elocation-id>.<pub-id pub-id-type="pmid"
1497
+ >29734470</pub-id></mixed-citation>
1498
+ </ref>
1499
+ <ref id="BRB3-2019-12-0787-bib-0023">
1500
+ <label>23</label>
1501
+ <?AuthorQuery id="Q11" queryText="CrossRef reports the title is &quot;2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC)&quot;. (Ref. 23 &quot;Mancia, Fagard, Narkiewicz, Red&#x00E1;n, Zanchetti, B&#x00F6;hm, Zannad, . . ., 2013&quot;)"?>
1502
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1503
+ ><string-name><surname>Mancia</surname>,
1504
+ <given-names>G.</given-names></string-name>,
1505
+ <string-name><surname>Fagard</surname>,
1506
+ <given-names>R.</given-names></string-name>,
1507
+ <string-name><surname>Narkiewicz</surname>,
1508
+ <given-names>K.</given-names></string-name>,
1509
+ <string-name><surname>Red&#x00E1;n</surname>,
1510
+ <given-names>J.</given-names></string-name>,
1511
+ <string-name><surname>Zanchetti</surname>,
1512
+ <given-names>A.</given-names></string-name>,
1513
+ <string-name><surname>B&#x00F6;hm</surname>,
1514
+ <given-names>M.</given-names></string-name>, <etal>. . .</etal>
1515
+ <string-name><surname>Zannad</surname>,
1516
+ <given-names>F.</given-names></string-name>, &amp; the <collab>ESH/ESC
1517
+ Task Force for the Management of Arterial
1518
+ Hypertension</collab></person-group>. (<year>2013</year>).
1519
+ <article-title>2013 Practice guidelines for the management of arterial
1520
+ hypertension of the <italic>European</italic> Society of Hypertension (ESH) and the European
1521
+ Society of Cardiology (ESC): ESH/ESC Task Force for the Management of
1522
+ Arterial Hypertension.</article-title>
1523
+ <source>Journal of Hypertension</source>, <volume>31</volume>,
1524
+ <fpage>1925</fpage>&#x2013;<lpage>1938</lpage>. <pub-id pub-id-type="doi"
1525
+ >https://doi.org/10.1097/HJH.0b013e328364ca4c</pub-id><pub-id
1526
+ pub-id-type="pmid">24107724</pub-id></mixed-citation>
1527
+ </ref>
1528
+ <ref id="BRB3-2019-12-0787-bib-0024">
1529
+ <label>24</label>
1530
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1531
+ ><string-name><surname>Boan</surname>, <given-names>A.
1532
+ D.</given-names></string-name>,
1533
+ <string-name><surname>Lackland</surname>, <given-names>D.
1534
+ T.</given-names></string-name>, &amp;
1535
+ <string-name><surname>Ovbiagele</surname>,
1536
+ <given-names>B.</given-names></string-name></person-group>
1537
+ (<year>2014</year>). <article-title>Lowering of blood pressure for recurrent
1538
+ stroke prevention.</article-title>
1539
+ <source>Stroke</source>, <volume>45</volume>,
1540
+ <fpage>2506</fpage>&#x2013;<lpage>2513</lpage>. <pub-id pub-id-type="doi"
1541
+ >https://doi.org/10.1161/STROKEAHA.114.003666</pub-id><pub-id
1542
+ pub-id-type="pmid">24984744</pub-id></mixed-citation>
1543
+ </ref>
1544
+ <ref id="BRB3-2019-12-0787-bib-0025">
1545
+ <label>25</label>
1546
+ <?AuthorQuery id="Q12" queryText="Medline reports the journal title should be &quot;CMAJ : Canadian Medical Association journal = journal de l&#x2019;Association medicale canadienne or CMAJ&quot;, not &quot;Canadian Medical Association Journal&quot;. (Ref. 25 &quot;McAlister, Majumdar, Padwal, Fradette, Thompson, Buck, Shuaib, . . ., 2014&quot;)"?>
1547
+ <mixed-citation publication-type="journal"><person-group person-group-type="author"
1548
+ ><string-name><surname>McAlister</surname>, <given-names>F.
1549
+ A.</given-names></string-name>,
1550
+ <string-name><surname>Majumdar</surname>, <given-names>S.
1551
+ R.</given-names></string-name>,
1552
+ <string-name><surname>Padwal</surname>, <given-names>R.
1553
+ S.</given-names></string-name>,
1554
+ <string-name><surname>Fradette</surname>,
1555
+ <given-names>M.</given-names></string-name>,
1556
+ <string-name><surname>Thompson</surname>,
1557
+ <given-names>A.</given-names></string-name>,
1558
+ <string-name><surname>Buck</surname>,
1559
+ <given-names>B.</given-names></string-name>, <etal>. . .</etal>
1560
+ <string-name><surname>Shuaib</surname>,
1561
+ <given-names>A.</given-names></string-name></person-group>
1562
+ (<year>2014</year>). <article-title>Case management for blood pressure and
1563
+ lipid level control after minor stroke: PREVENTION randomized controlled
1564
+ trial.</article-title>
1565
+ <source>Canadian Medical Association Journal</source>, <volume>186</volume>,
1566
+ <fpage>577</fpage>&#x2013;<lpage>584</lpage>. <pub-id pub-id-type="doi"
1567
+ >https://doi.org/10.1503/cmaj.140053</pub-id><pub-id pub-id-type="pmid"
1568
+ >24733770</pub-id></mixed-citation>
1569
+ </ref>
1570
+ </ref-list>
1571
+ </back>
1572
+ <floats-group>
1573
+ <graphic content-type="leading" xlink:href="fig1.png">
1574
+ <alt-text>example of alt text for hero-image</alt-text>
1575
+ <long-desc>example of long desc for hero image</long-desc>
1576
+ </graphic>
1577
+ </floats-group>
1578
+ </article>